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Synthetic Dna Technology As A Tool To Generate Vaccine Immunity In The Skin
Abstract
Since DNA’s ability to generate an immune response was first described over 25 years ago, much work
has been done to realize DNA’s full potential as a safe and potent vaccine candidate. Renewed research
has focused on continually improving the potency of the platform, which has led to advancements in
electroporation, DNA formulation, and novel synthesized sequence optimizations, allowing newer
“synthetic” DNA vaccines (SDNA) to contend as a major vaccine platform. Further insights into factors
that influence SDNA vaccine outcomes are critical to achieving full potential. Here, we designed novel
SDNA encoded skin-derived cytokines within the IL-36 family, to assess their impact on immunity against
several viral targets. Zika virus challenge studies were also performed to assess whether observed
adjuvant activity led to improved challenge outcome. The studies show that codelivery of optimized IL-36
gamma, with a non-protective dose of a Zika SDNA vaccine, can enhance immune responses, allowing for
protection against challenge compared to nonadjuvanted mice. Another important area that is relatively
understudied is skin delivery of SDNA vaccines. The skin is a major immune organ, and expanded
applications for immunization might be possible with better understanding of its potential in the context
of newer SDNA technology. To test the impact of skin vaccination on a relevant pathogen challenge, two
consensus SDNA vaccines that encode a Leishmania antigen, PEPCK, were designed incorporating
several genetic improvements including RNA and codon optimization and addition of a highly efficient IgE
leader sequence. These were used to immunize mice intramuscularly or intradermally and analyze the
resulting immunity. We observed that intradermal vaccination drove a greater number of antigen specific
skin resident T cells in the skin compared to intramuscular vaccination, both at the vaccination and distal
site. We further observed that mice immunized intradermally were better protected against parasite
challenge and burden compared to intramuscularly immunized mice. My thesis supports the idea that the
skin represents both a robust source of important immune modulators that can improve vaccination
outcome and a unique site for SDNA immunization that gives rise to long lived resident immune cells
which may play a crucial role in generating effective interventions against infectious agents and cancer.
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ABSTRACT

SYNTHETIC DNA TECHNOLOGY AS A TOOL TO GENERATE VACCINE IMMUNITY IN THE
SKIN
Lumena Louis
David B. Weiner

Since DNA’s ability to generate an immune response was first described over 25 years ago,
much work has been done to realize DNA’s full potential as a safe and potent vaccine candidate.
Renewed research has focused on continually improving the potency of the platform, which has
led to advancements in electroporation, DNA formulation, and novel synthesized sequence
optimizations, allowing newer “synthetic” DNA vaccines (SDNA) to contend as a major vaccine
platform. Further insights into factors that influence SDNA vaccine outcomes are critical to
achieving full potential. Here, we designed novel SDNA encoded skin-derived cytokines within the
IL-36 family, to assess their impact on immunity against several viral targets. Zika virus challenge
studies were also performed to assess whether observed adjuvant activity led to improved
challenge outcome. The studies show that codelivery of optimized IL-36 gamma, with a nonprotective dose of a Zika SDNA vaccine, can enhance immune responses, allowing for protection
against challenge compared to nonadjuvanted mice. Another important area that is relatively
understudied is skin delivery of SDNA vaccines. The skin is a major immune organ, and
expanded applications for immunization might be possible with better understanding of its
potential in the context of newer SDNA technology. To test the impact of skin vaccination on a
relevant pathogen challenge, two consensus SDNA vaccines that encode a Leishmania antigen,
PEPCK, were designed incorporating several genetic improvements including RNA and codon
optimization and addition of a highly efficient IgE leader sequence. These were used to immunize
mice intramuscularly or intradermally and analyze the resulting immunity. We observed that
vi

intradermal vaccination drove a greater number of antigen specific skin resident T cells in the skin
compared to intramuscular vaccination, both at the vaccination and distal site. We further
observed that mice immunized intradermally were better protected against parasite challenge and
burden compared to intramuscularly immunized mice. My thesis supports the idea that the skin
represents both a robust source of important immune modulators that can improve vaccination
outcome and a unique site for SDNA immunization that gives rise to long lived resident immune
cells which may play a crucial role in generating effective interventions against infectious agents
and cancer.
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“ And most importantly, I know that we need to directly teach our children the most vital lessons,
rather than assume that they’ll be understood.” Galit Breen
Scene: Lumena, age 5 having a full-blown meltdown at having to take the TDp/dTp vaccine
“I DON’T CARE that it’s good for me. I hate needles, and I don’t want to take this shot!!!!” (tears
streaming down young Lumena’s face)
“It will be over before you know it. Just a little pinch and that’s it!” (exasperated nurse who just
wants to get on with her day).
“Don’t cry, don’t be scared. You need this shot. You don’t want to get sick if something happens,
do you? This will help prevent that. We’ll go to Mcdonald’s afterwards.” (Lumena’s mom trying to
bribe and distract her from this scary needle about to go in her arm).
“Can I get some help in here?” (nurse calling for coworkers to help her and mom hold down
Lumena’s limbs to administer the shot)
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CHAPTER 1- Introduction
The skin as a protective barrier and immune organ
th

Early vaccination efforts can be traced back to the practice of variolation during the 16 century in
China, as a means of protection against the debilitating and oftentimes scarring and deadly
effects of smallpox (Boylston 2012). In some of the earliest records documented, accounts of
people inhaling dried and crushed smallpox scabs from the skin of an infected person to protect
against severe disease show that even early on, there was some understanding of pathogen
th

exposure and resulting immunity. It was not until the 18 century when Edward Jenner, a
physician scientist, remarked early in his life that milkmaids who were exposed to cowpox
appeared immune to smallpox, created the first successful vaccine against smallpox that the
observed protection of inoculated cowpox against smallpox was fully realized (Plotkin 2014).
Smallpox remains the only human disease fully globally eradicated as of today.
The modern day smallpox vaccine is made of live vaccinia virus and is delivered to the skin of the
arm by puncturing the skin with a bifurcated needle 15 times (Belongia and Naleway 2003).
Precaution must be taken to prevent the live virus from spreading from the site of vaccination,
however very serious adverse complications from vaccination are relatively rare. The smallpox
vaccine has historically had an efficacy rate of 95%, with life long immunity, which was commonly
attributed to the immunogenicity of the virus. However, a study comparing the delivery of the
smallpox vaccine in the skin to delivery in the muscle has shown that given the same dose,
intradermally vaccinated mice are better protected against smallpox challenge compared to
intramuscularly immunized mice (Liu et al. 2010). The same result was observed in a melanoma
model, supporting the ability of the skin to play a major role in facilitating a robust, protective
immune response enhancing the immunogenicity of the delivered vaccine antigen.
The skin is the largest organ of the human body and plays a major role in maintaining several
homeostatic processes in the host (Gruber and Schmuth 2014). These processes include
1

waterproofing, limiting dehydration, providing strength and flexibility, regulating pigmentation, and
maintaining insulation. Skin is made up of three physical layers: the epidermis, the dermis, and
subcutaneous layer (Losquadro 2017). In addition to providing a physical barrier, the skin also
acts as a first line immune defense through which the innate and adaptive arms can be activated.
This occurs by way of a number of cell types that reside in the skin, including keratinocytes,
+

+

melanocytes, CD4 and CD8 T cells, Langerhans cells, dendritic cells, macrophages, natural
killer cells, innate lymphoid cells and fibroblasts (Abdallah, Mijouin, and Pichon 2017).
Keratinocytes, which make up approximately 95% of the skin are primarily thought to ensure the
skin’s structural integrity (Eckert 1989). In addition to their physical function, keratinocytes are
often considered immune guard keepers, for their ability to sense a number of external stimuli
and in response secrete a number of cytokines, chemokines, and antimicrobial peptides (Nagy
and Kemény 2009). These molecules can either recruit other immune cells or directly destroy the
offending material. Molecules in this category include IL-1, IL-10, TNF-α, TGF-β, IL-6, G-CSF,
IP-10, CXCL-8, cathelicidins and β-defensins and possibly others (Hesse‐Macabata et al. 2019).
Keratinocytes can also engage in cross talk with dendritic and T cells, further engaging the
adaptive response and initiating a cascade to facilitate immune memory.
Langerhans cells (LCs), members of the dendritic/macrophage family, are considered the major
antigen-presenting cell located in the epidermis (Mutyambizi, Berger, and Edelson 2009). They
play a major role in immune tolerance during normal physiologic conditions, and a critical role in
initiating inflammatory events when danger is present. LCs extend their dendritic processes
between intercellular tight junctions to sample the environment in the uppermost regions of the
skin, and are likely the first cells that skin-invading pathogens encounter (Deckers, Hammad, and
Hoste 2018). It has been established that LCs express major histocompatibility complex II (MHC
+

II) and can therefore present antigens to CD4 T cells. There is some conflicting data in the field
+

whether true LCs express MHC I and cross present to CD8 T cells, however it is evident that
2

LCs play a major role in initiating innate and adaptive immune responses. LCs can capture and
process antigens through the pattern recognition receptor (PRR) Langerins (Clayton et al. 2017),
and then migrate to local draining lymph nodes where they can interact with naïve T and B cells
in order to initiate the adaptive immune response.
T cells found in the skin are usually either resident or effector T cells that are antigen experienced
(Clark 2015). After the initial proliferation of a naïve T cell that has been activated by an APC, a
contraction in the number of T cells specific for an antigen occurs, however T cells can persist at
numbers higher than before antigen encounter even after infection clearance. Data support that
the T cells that remain help maintain memory against the pathogen, so that the immune response
mounted upon a second encounter will be more rapid and of greater magnitude. A subset of
these T cells will remain effector memory T cells (TEM), where they travel around the body outside
of the lymphoid tissues fighting off secondary infections (Gray, Westerhof, and MacLeod 2018).
Exciting work in the T cell field has begun to identify distinct subpopulations of T effector cells,
+/-

+

including Tcf1 PD-1 cells, which appear to be critical for stem-like renewal of effector cells,
especially in the context of cancer, tumor burden control, and T cell exhaustion (Siddiqui et al.
2019). Another subset of T cells will become resident memory T cells (TRM), where they are
thought to remain indefinitely in the tissue and do not recirculate (Carbone 2015). These T cells
fight off infection directly in the tissue and are considered to be the first line defense against
pathogen reencounter. TRM are generally found in epithelial tissues where there is constant
exposure to the outside environment, including the skin, gut, and lungs (Shin and Iwasaki 2013).
DNA vaccine technology and the skin
Vaccines are considered among the top accomplishments of modern medicine, saving
millions of lives by inducing immunity to a number of infectious pathogens. As the next generation
of vaccines seeks to address ever more complicated targets including cancer, innovative
technologies like synthetic DNA vaccination that circumvent some of the issues associated with
3

traditional vaccines will likely prove critical. In addition, compounding factors that may influence
immune outcome such as the microbiome both in the gut and skin must also be studied in greater
detail. Recent clinical studies have suggested that the presence of certain bacteria in the gut is
associated with favorable outcomes in patients receiving immunogenic chemotherapy (Routy et
al. 2018). Other studies have also shown that a dysbiosis or overrepresentation of certain
bacteria strains was negatively associated with favorable outcome. A recent clinical study found
that volunteers with low pre-existing antibody titers to the influenza virus or vaccine that took a 5
day broad spectrum antibiotics course had impaired responses to an influenza vaccine (Hagan et
al. 2019), further implicating the importance of the biome on vaccine induced immunity in
humans. Further work needs to be performed to more fully understand the influence that the
microbiome exerts on the immune system and vice versa, and the significance of this relationship
in designing future therapies.
History of DNA vaccines: New and Improved
Following the initial reports of DNA’s ability to be used as an immunogen for generating an
immune response over twenty five years ago, significant work has been focused to realize DNA’s
intrinsic potential as a safe and potent vaccine platform in a variety of contexts, including
infectious diseases and cancer applications. While an enormous amount of exciting preclinical
animal model data has been generated, until recently, despite the platform’s safety, translation
from small animal models to larger animals with robust immunity, as well as in the clinic was not
achieved. However, recent advancements, including improved technologies for DNA delivery,
improved concentrated formulations, improved stability of product, rapid production, improved
construct sequence design including genetic optimizations focusing on RNA changes as well as
codon optimization, non native leader sequences, and the inclusion of genetic adjuvants, have
begun to establish this new synthetic DNA platform as a serious partner for rapid development for
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multiple applications and in particular for rapid protection against emerging infectious disease
threats.
In the early 1990s, four separate groups reported that plasmid gene delivery resulted in in vivo
expression and immune responses against the antigen. In 1992, Tang and Johnston reported the
delivery of human growth hormone (HGH) DNA to the skin of mice using a gene gun (Tang,
DeVit, and Johnston 1992), believing that this could be a useful technique for gene therapy,
however the gene therapy approach was not effective as the plasmid delivery resulted in
antibodies against the HGH encoded protein. Separately, at the Cold Spring Harbor vaccine
meeting in 1992, Margaret Liu along with her colleagues at Merck (Ulmer et al. 1993), as well as
Harriet Robinson (Fynan et al. 1993), from the University of Massachusetts, described DNA
plasmid’s ability to drive immune responses against influenza virus using plasmid delivered
antigens, while David B Weiner reported that plasmids encoding constructs for HIV or tumor
antigens could induce neutralizing antibody responses as well as CTL’s resulting in protection
against tumor challenge (B. Wang et al. 1993). These three reports were soon published and
stood as evidence to the vaccine field that a new technology consisting of deceptively simple
DNA delivery could serve as a simple immunization platform in a number of models. These early
experiments in mice were to face immune potency issues over the next few years in larger animal
models.
The vaccine field however, was excited by these initial studies. DNA vaccines have multiple
conceptual advantages over traditional killed, live attenuated, and viral vector based vaccines
(Table 1). DNA is simple to work with, allowing for relatively easy manipulation for a variety of
applications. DNA vaccines are nonlive and nonreplicating, eliminating the risk of
attenuation/reversion and also allow for safe delivery in high-risk populations, including persons
who may be immunocompromised. DNA vectors are themselves not immunogenic, allowing for
repeated administration without immune interference or concerns regarding previous viral
5

exposure limitations. In addition, DNA in theory can be manufactured to be more stable than
traditional viral and killed vaccines thus possibly improving reliance on a complete cold chain,
which in turn makes it an ideal candidate for important products developed for resource strained
settings.
DNA vaccines contain antigen sequences that encode for a particular part of a pathogen or
tumor, and are inserted into a mammalian plasmid expression vector. The vector now becomes
the new vaccine. Following production, this plasmid vector can be delivered intradermally or
intramuscularly, i.e. locally to tissues, where upon cell entry, some of the delivered plasmid will
enter the nucleus of transfected cells and plasmid-encoded sequences will drive host cell
transcription, producing the protein in vivo. This now in vivo produced foreign protein, can be
expressed both in the transfected cells as well as released from these transfected cells to be
recognized by immune cells. The protein can become subject to immune surveillance allowing for
presentation of this now foreign antigen on the Class I and Class II antigen presenting systems.
The native host system responds to this foreign antigen by eliciting a response including both
antibodies (B cell responses) as well as cellular immunity (T cell responses), which can be
protective in animal challenge models (Kutzler and Weiner 2008).
Due to the conceptual advantages in simplicity, production, and storage of DNA vaccines over
traditional live as well as nonlive platforms, and the success seen in most small animal preclinical
models, excitement regarding the outcome of the DNA platform in humans seemed all but
assured. However, as early human clinical trials failed to display the same level of immune
response observed in preclinical studies, concerns mounted. The platform was well tolerated in
people, but these initial vaccines were poorly immunogenic in the clinic. These results soon
repositioned DNA to take a backseat as a primary immune approach, and opened up a new
secondary role for DNA vaccines as a component in prime boost model systems (Kardani,
Bolhassani, and Shahbazi 2016; Woodland 2004; McCormack et al. 2008). In these systems,
6

DNA is used as an initial priming immunization to focus and jumpstart the immune response, and
then either protein or viral vector is used in subsequent boosting immunizations. This combined
approach led to greater immune responses compared to either platform alone and helped the
viral vector approach partially avoid the host immune response.
Almost 20 years after their debut, the technology that underpins the first generations of DNA
vaccines has been reexamined and reengineered with the goal of improved potency and
consistent immune induction in the clinic. The initial vaccines utilized dilute formulations of DNA,
limiting the DNA dose that could be delivered, thereby limiting the efficacy of the vaccine. Today,
due to new formulations (Ferraro et al. 2011; Suschak, Williams, and Schmaljohn 2017; Grunwald
and Ulbert 2015), much more highly concentrated SDNA plasmids are utilized, at doses upward
of 10 mg/ml, which can increase vaccine efficiency. In addition to being more concentrated,
newer formulations can be developed that are much more stable, reducing the need for complete
cold chain transport, broadening the use of this approach in resource strained settings where total
refrigeration or freezing may present challenges.
Genetic sequence optimization: moving on up to better expression
In addition to improving SDNA delivery concentrations, a vast amount of work has gone into
optimizing the genetic sequence of these vaccines. One approach has been to carefully select
the antigen sequence to encode for codons that target preferred transfer DNAs (tDNAs) for any
given species (Ravi Vijaya Satya, Amar Mukherjee, and Udaykumar Ranga 2003). It’s thought
that codons that target more abundant tDNAs are translated more efficiently and thus express
more antigen, potentially increasing immunogenicity of the SDNA vaccine. RNA optimization has
also enhanced SDNA vaccine improvement. By eliminating elements that encourage RNA
secondary structures such as stem loops, which can stall and disrupt mRNA transport, the mRNA
transcripts are stabilized and allow for high antigen expression.

7

Further plasmid modifications that have contributed to improved SDNA expression include the
inclusion of a more efficient PolyA signal (Montgomery et al. 1993; Hartikka et al. 1996), which
terminates transcription and allows mRNA to be exported out of the nucleus. The use of
nonnative leader sequences, such as the efficient IgE leader sequence (Kutzler et al. 2005; S.
Wang et al. 2006), can stabilize mRNA and increase translation efficiency, further enhancing
antigen expression. The development of smaller plasmids has effectively increased plasmid
concentration in a given volume, allowing for more SDNA to be delivered per “dose.”
Electroporation Technology: an electric solution to an old delivery problem
The use of new, more potent delivery technologies combined with the new DNA formulations
further advanced the field. Specifically, the use of newer and reengineered electroporation (EP)
devices to enhance in vivo transfection of delivered DNA during immunization, can result in a
100-1000x increase in transfection efficiency (Sardesai and Weiner 2011). The application of an
electric field immediately upon DNA injection enhances DNA uptake in two ways: EP creates
transient pores in the membrane where the DNA can enter the cell, and also generates an
electric field to drive the DNA into those cells as well. These activities combine to boost DNA
uptake, creating a large bolus of foreign protein in vivo, ultimately driving improved immune
responses against the vaccine. Although older electroporation technology was initially
considered too harsh to routinely use in humans, advances in the EP field including computer
driven devices, lowered voltages, resistance sensors with controlled current and timing settings,
have all led to a more tolerable experience in people, and dramatically improved vaccine take,
making EP a viable candidate in vaccine development. As a consequence of these advances,
delivery of DNA vaccines by EP in large animal models has led to increased cellular and humoral
immune responses, rivaling those seen with viral vectors. Importantly, advanced EP that takes
advantage of higher concentrated formulation and targets skin delivery may be particularly
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relevant for emerging infectious diseases (EID) settings, where robust and rapid immune
responses are necessary.
Harnessing the immune system’s messengers as potential adjuvants to DNA vaccines
Adjuvants have had a long history in the vaccine field, and have been primarily used to increase
immunogenicity of various vaccines. Formulated adjuvants can function through a number of
mechanisms, including enhanced antigen uptake and presentation, antigen depot formation, and
activation of the innate immune system. Alum is currently the most widely used adjuvant in
licensed vaccines, and while it has been successful at increasing vaccine responses, alum mostly
enhances Th2 humoral responses, thus limiting its use in vaccine platforms where enhanced
cellular responses are desired. Other materials, including oil-in-water emulsions have also been
studied as potential adjuvants. AS03, produced by GSK (Garçon, Vaughn, and Didierlaurent
2012), contains α-tocopherol and squalene, and has been shown to enhance vaccine specific
humoral immune responses by increasing antigen uptake and presentation. In the clinic, AS03
was incorporated in the pandemic H1N1/2009 vaccine and showed increased vaccine
immunogenicity compared to non-adjuvanted vaccine. AS04, an adjuvant that is comprised of
monophosphoryl lipid A and alum, is licensed and used in the human papillomavirus (HPV)
vaccine Cervarix. A number of nontraditional adjuvants are being investigated as well, including
pathogen-recognition receptor (PRR) agonists, nanoparticles, liposomes, and gene-encoded
adjuvants (Lee and Nguyen 2015). PRR agonist adjuvants, including Toll-like receptor (TLR)
ligands, exploit innate immune signaling, jumpstarting the body’s first line of defense. This in turn
can work in concert with the adaptive immune system to generate lasting memory against the
antigen. TLRs are generally expressed by macrophages and dendritic cells that are constantly
surveying for conserved pathogen associated molecular patterns (PAMPs) derived from microbes
that breach initial physical barriers (Coffman, Sher, and Seder 2010). Their role for enhancement
of gene encoded vaccines remains to be determined.
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Gene encoded adjuvants, such as cytokine DNA sequences, have also been studied as potential
adjuvants for DNA vaccines. Cytokines are small proteins expressed by leukocytes and other
non-immune cells that modulate the immune system. By delivering cytokines at the site of
vaccination, it is possible to specifically tailor the immune response to adequately respond to
future challenges. Gene encoded cytokine delivery allows the cytokine to be present at the same
time as the antigen, increasing the likelihood that the cytokine can act within the window period
where initial immune responses are occurring. Another advantage of delivering cytokines at the
site of immunization is the avoidance of systemic exposure, which can reduce the risk of systemic
side effects. A vast number of cytokines have been studied as potential adjuvants, including IFNα, GM-CSF, Flt-3 ligand, IL-18, IL-21, IL-15, IFN-γ, IL-12, and IL-2 (Taylor 1995; Tovey and
Lallemand 2010), in a number of experimental models; importantly, much work still needs to be
done in the vaccine field regarding these cytokines as potential adjuvants.
In the context of DNA gene encoded adjuvants, Interleukin 12 (IL-12) has established an
important potency track record for several years and is the most studied cytokine DNA adjuvant in
the clinic. IL-12 is a pro-inflammatory cytokine primarily secreted by dendritic cells that links the
innate and adaptive immune response, promoting enhanced Th1 cellular responses. Given its
potent Th1 activation, there has been a lot of interest in using IL-12 as an adjuvant in various
vaccine platforms, most notably in cancer trials. Early trials where IL-12 protein was delivered
systemically resulted in major side effects, limiting potential use. However, local delivery of
plasmid encoded IL-12 (pIL-12) does not drive systemic toxicity in the clinic (Schadeck et al.
2006; Sin et al. 1999; Tugues et al. 2015; Cha and Daud 2012; Kalams et al. 2012). Multiple trials
have studied pIL-12 as an adjuvant administered as DNA formulated as part of the plasmid
vaccine. In this delivery, the IL-12 adjuvanted vaccines have been well tolerated and some of
these studies have seen clear immune improvements from the presence of IL-12 adjuvant. A
recent study by Kalams et al is illustrative (Kalams et al. 2013). In this study the combination of
EP + IL-12 drove much improved T cell responses for both CD4 and CD8 immunity. This HIV
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Vaccines Trials Network (HVTN) study that combined plasmid encoded human immunodeficiency
virus (HIV) antigens encoding Gag/Pol and Env +plasmid IL-12 +EP described that the
combination approach resulted in overall T cell response rates of 90%, which were similar to
combination vaccine studies that required boosting with viral vectors. As another example, a
clinical trial that used a multi antigen HIV DNA prime and vesicular stomatitis virus (VSV) Gag
protein boost with increasing doses of plasmid DNA IL-12 found that there were increased CD8

+

T cell responses in people adjuvanted with plasmid IL-12 compared to those whose vaccine was
+

not adjuvanted (S. S. Li et al. 2017). The CD8 T cell responses observed post boost were also
enhanced compared to non-adjuvanted groups. As more clinical trials are performed testing IL12’s potential as an adjuvant in the DNA + EP setting in additional disease models, we will gain
additional insight into the immune activity of these combined approaches.
This initial data has encouraged the study of many additional cytokines, including those whose
functions are less well understood, but appear to be interesting as potential adjuvants for DNA
vaccines. Villarreal et al. showed that IL-33, an alarmin that is thought to alert the immune system
to different stimuli and tissue damage was able to act as an immune adjuvant and enhance
immune responses in tuberculosis, LCMV, and cancer animal models (Villarreal et al. 2014;
Villarreal, Siefert, and Weiner 2015; Villarreal and Weiner 2014). Villarreal further advanced the
field in showing that although IL-33 was traditionally thought to only drive Th2 humoral responses,
+

it has the ability to drive Th1 and CD8 cellular functions as well.
There is a lot of exciting research currently being done in the field to find new potent adjuvants to
boost immune responses to vaccines, including research on adjuvant delivery systems,
combination studies and plasmid codelivery (Saade and Petrovsky 2012; Temizoz, Kuroda, and
Ishii 2016). Adjuvants have the potential to reduce vaccine dose and frequency, overcome
immune senescence, and allow for new vaccine targets. A special focus on adjuvants that can be
delivered to the skin may prove advantageous, given the number of antigen presenting
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Langerhan cells found in this tissue as well as the critical immune interactions constantly
occurring at this site.
The microbiome and vaccine induced immunity
Appreciation has grown over the last 20 years that the human body provides a home to more
than ~60 trillion microorganisms, of which at least half are bacterial. This is collectively referred to
as the microbiome. It has become apparent that the microbiome is a major important piece of our
biology that impacts health on many levels, and this eclectic collection of microorganisms is
critical for maintaining homeostasis in the human system. As more is understood about the
microbiome, thoughts about plasmid delivery for prophylactic and therapeutic applications are
also evolving. On average, the bacteria that comprise our microbiomes will have a life span of
between 12 and 24 hours, thus continually exposing the host to plasmid and bacterial DNA
naturally. The FDA has expressed some concern regarding the delivery of DNA as a vaccine
platform, however the small amount of DNA that we additionally deliver in a DNA vaccine is likely
of little consequence in this grand scheme.
One particular area of interest for the vaccine field is the role that the microbiome may play in
vaccine-induced immune responses (Deriu et al. 2016; Shi et al. 2017; Ichinohe et al. 2011;
Round and Mazmanian 2009). Recent data suggests that the types of bacteria and relative
amounts of each type of bacteria may directly impact the efficacy of vaccines. Microbial cells are
primarily found in the intestinal tract, as well as the skin, bronchial and genital tract. Studies using
germ free mice or those treated with antibiotics to deplete intestinal bacteria have shown
defective innate immune responses to infectious diseases including influenza. Upon microbiome
restoration, proper immune responses were also restored. These studies also showed the
importance of the strain of bacteria. Mice that were colonized with flagellated E. coli mounted the
appropriate immune response against influenza A, whereas mice colonized with non-flagellated
E. coli did not. Given that the microbiome is largely established within the first 6 months of life,
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around the same time that many vaccines are first administered, additional study of these early
colonizers in this context will be important. In a striking study, researchers compared the
microbiome of infants from Ghana and the Netherlands that were vaccinated against rotavirus
and found that the Dutch infants were generally able to mount a strong immune response to the
vaccine, while many Ghanaian infants were unable to do so (Harris et al. 2017). Of the Ghanaian
infants that did mount an immune response, their microbiomes were much more similar to the
Dutch infants compared to the microbiomes of the nonresponders. The implications of this study
suggest that the microbiome may play a significant role in vaccine outcomes in diverse
populations. In a clinical study published this year examining the impact of the microbiome in
influenza vaccine induced immune responses, Hagan et al found that adults with high pre-existing
titers to the vaccine did not exhibit impaired antibody responses after taking a course of broad
spectrum antibiotics, despite a 10,000 fold decrease in gut bacterial load (Hagan et al. 2019).
However, in adults that had low titers to the vaccine beforehand, antibody responses to a specific
strain in the vaccine were greatly impaired. Interestingly, the study also found that these
individuals exhibited similar inflammatory responses as those observed in older people that
struggle to adequately generate robust immunity to the influenza vaccine. As the number of
clinical trials that test the impact of more tolerable and less invasive vaccine programs such as
intradermal vaccine delivery increases, understanding the potential immune interactions between
local bacteria on the skin and the immune cells critical in the primary immune response will
become increasingly important.
As the era of therapeutic vaccine mediated approaches for cancer is well underway, the influence
of the microbiome cannot be understated. Clinical studies that have evaluated the effectiveness
of immune-checkpoint inhibitors that target PD-1 or CTLA-4 found a positive association between
the presence of bacteria such as Akkermansia muciniphila, Bifidobacterium spp., and
Faecalibacterium and anti-cancer outcomes (Routy et al. 2018). Characterization of the gut
microbiome of patients with metastatic melanoma treated with anti-PD1 antibodies showed that
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those who responded to the therapy had a greater abundance of bacteria from the
Ruminococcaceae family. Future trials must be performed to determine whether the microbiome
can influence therapeutic outcome in other disease models. In a clinical HPV DNA vaccine study,
50% of vaccinated women regressed their disease overall. 40% of these women actually
eliminated the precancer, cleared their underlying HPV16/18 infection, and exhibited complete
histopathologic regression compared to only 14.3% in the placebo group (Trimble et al. 2015).
While this represents an important breakthrough as the first therapeutic vaccine to show efficacy
against cervical intraepithelial neoplasia grade 2/3 (CIN2/3) associated with HPV16/18, there is
still a lot of work needed to elucidate some of the differences between the women who responded
and those that did not. Interestingly, some patients were able to regress, but did not clear the
underlying infection. As the urogenital tract itself is home to a unique microbiome, a study of the
bacteria populations in the patients who cleared and regressed, regressed but did not clear, or
didn’t respond is certainly worth investigating.
Lessons learned in rapid vaccine development in the midst of infectious outbreaks
Recent global events have highlighted the need for rapid, effective vaccine development for
emerging infectious diseases. The World Health Organization (WHO) warned a decade ago that
infectious pathogens were emerging and reemerging at rates unseen before. Traditional vaccines
have been developed on the scale of years, which is not ideal in the midst of a sudden epidemic,
as illustrated by the 2014-2016 Ebola outbreak. In response to this particular outbreak, many
groups set out to create therapies and vaccines that could impact these outbreaks, treat those
who were infected, or prevent transmission to those that were uninfected. The recent Zika
emergency is a case in point. Very rapidly after the Zika epidemic was reported, a synthetic DNA
vaccine was engineered to generate immunity against the Envelope protein of Zika and designed
for skin delivery using high concentration formulations of the DNA in a very small volume
(Muthumani et al. 2016). As part of the design, the vaccine contained sequences encoding the
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precursor membrane (prM) region to help with transport and processing of the Envelope (E)
antigen. After very encouraging preclinical data, the vaccine was moved to the clinic in just over
6 months and became the first Zika vaccine in human clinical testing (Figure 1). The clinical trial
sought to answer whether there was some advantage to delivering the vaccine intradermally vs
intramuscularly, and found that volunteers that were immunized in the skin had stronger antibody
and cellular responses to the vaccine compared to those immunized in the muscle. The synthetic
prME vaccine induced rapid seroconversion in greater than 95% of volunteers by two
immunizations and 100% seroconversion after 3 immunizations (Tebas et al. 2017). Importantly,
the induced antibodies from this study were able to protect immune deficient mice from a lethal
Zika virus challenge by passive transfer, suggesting that the antibodies developed through
vaccination in vaccine volunteers may be sufficient to protect against subsequent exposure to the
virus. Additionally, T cell responses were induced in most vaccine recipients in this study,
suggesting the activation of both arms of the adaptive immune system. The use of newer SDNA
technologies for outbreak strategies that can be rapidly moved to the clinic appear to be finally
establishing an important track record for safety, speed and immune potency. Furthermore, the
relative ease of intradermal vaccine delivery will likely enhance vaccine uptake in a number of
diverse settings.
Looking to the future
With increased globalization and climate change, novel infectious diseases are an expanding
threat to previously unaffected areas, underscoring the need for rapid development of new
vaccines. The National Institute of Allergy and Infectious Diseases (NIAID) Biodefense program
maintains a record of infectious pathogens and diseases it considers top priorities, which paints a
sobering picture of the work ahead for the field (Figure 2). In addition to newly emerging
infections, some previously known pathogens can mutate to give rise to new strains that may
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trigger pandemics. In tackling these pathogens, lessons learned from the Ebola, Zika, and MERS
outbreaks can help guide future vaccine programs.
The SDNA platform has significant potential to contribute to rapidly impacting new outbreaks.
Collective advancements to the platform, including higher concentrations of product and improved
delivery methods for enhanced EP targeting ID space for example, have begun to alter DNA’s
reputation, supporting it as a viable candidate for prophylaxis and therapy options. The inherent
properties of plasmid DNA production, including low manufacturing costs, excellent safety profile,
rapid scale up potential, high immune response rate of vaccines and short time to clinic, are
highly encouraging, especially as the number of efficacy trials is growing. As the platform
continues to evolve and target discovery becomes more precise, the promise of this new
generation of DNA technologies will be further tested and refined.

* Modified from: Louis L, Weiner DB. (2019). Rapid Synthetic DNA vaccine/immunotherapeutics
for infectious disease and cancer targets. Microbiome and Cancer. Current Cancer Research
(347-362)
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Table 1. Comparison of Various Vaccine Platforms.
Table compares a number of parameters of different vaccine platforms.
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-

Yes

Original Gardasil vaccine

6 years from bench to clinical trials; 13 years to approval
1991
Jian Zhou
and Ian
Frezer make
non
infectious
virus like
particles
(VLP)

1997
Merck begins
initial in
human
clinical trials

2004
FDA
approves
Gardasil
vaccine

ZIKV-prME candidate vaccine

6.5 months from bench to clinical trial
2015
Zika outbreak
reported

2016
UPenn, Inovio,
GeneOne
begin in
human clinical
trials

Figure 1. Timeline comparing the development of Gardasil and ZIKV prME vaccines.
This is an illustration of the major time points in the development of the original Gardasil vaccine.
From the development of VLPs, it took 6 years to begin clinical trials, while it took six and a half
months from the time of initial reports on Zika outbreak to a clinical trial testing the Zika SDNA
vaccine, highlighting the potential of the DNA vaccine platform to rapidly develop candidate
vaccines during outbreaks.
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Figure 2. Diagram of emerging infectious diseases according to NIAID.
The diagram highlights a number of infectious pathogens and diseases that the National Institute
of Allergy and Infectious Diseases (NIAID) Biodefense program considers top priorities. In
addition to newly emerging infections, there are also a number of pathogens that have mutated to
give rise to new strains that may trigger pandemics. Patterns of climate change, increased travel,
as well as genetic mutations have all contributed to this growing list.
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Goals of this thesis project
As the newer DNA technology continues to improve, there is a need to fully maximize its
potential in previously under explored areas. DNA vaccination and immune response in the
context of skin, particularly cellular responses, is one such example. One goal of my thesis
project was to evaluate the potential of a skin derived cytokine, IL-36, to act as an adjuvant to
complement and enhance DNA vaccine-induced cellular responses. The need for novel
+

adjuvants that can boost CD8 T cell responses will continue to grow, and the concept of skin
specific adjuvants for DNA has not been previously explored. These adjuvants may be especially
+

useful in cancer applications where CD8 T cells are critical for tumor control, or for vector borne
infections, which frequently originate at cutaneous sites. For initial studies, we encoded both full
length and truncated forms of IL-36 in a plasmid and assessed whether there was a difference in
the immune responses observed following vaccination given reports of increased bioactivity upon
truncation. We then tested the cytokine with a number of disease antigens to assess whether it
could be used in a variety of vaccine models to boost immunity, and lastly observed whether any
enhanced immunity provided by IL-36 could protect in an established Zika challenge model. We
further sought to examine whether cellular responses induced by IL-36 could provide protection in
a model where antibody mediated protection is thought to be most important.
The immune responses generated by intradermal DNA vaccination, especially cellular responses,
have not been fully explored. The Zika clinical study mentioned earlier, as well as an RSV DNA
vaccine study in the cotton rat, both used an intradermal delivery approach, however these
studies primarily focused on induced humoral responses. Another major goal of my thesis project
was to examine the cellular responses generated during intradermal DNA vaccination and to
investigate whether these immune responses generated would be protective in a challenge model
where cellular responses are critical. For our initial studies, we assessed the immune responses
generated by intradermal vaccination of an established HIV DNA vaccine to ensure the broad
application of this strategy across multiple antigens and disease models. I also focused on the
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development of a new consensus DNA vaccine against a newly described Leishmania antigen,
which has been reported to have ability to induce protective immune responses against challenge
as a peptide-based immunogen. This early study was exciting but not confirmed in a follow up
study. Accordingly, I was interested in assessing whether intradermal delivery of a DNA encoded
vaccine could induce potent immune responses at the site of immunization and impact protection
in an important pathogen challenge.
Ultimately, the main goal of my thesis project was to determine if the skin could be mined, both as
a site of vaccination and as a provider of immune messengers, to further advance and improve
the DNA vaccine platform as the demand for new technologies to address ever more challenging
targets increases.
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CHAPTER 2- MATERIALS AND METHODS

Cell lines. HEK293T and U2OS cells were purchased from ATCC and grown in Dulbecco’s
Modified Eagle Medium (DMEM) (Invitrogen) with 10% heat inactivated FBS and antibiotics
(Invitrogen; 100 units/mL Penicillin and 100 µg/mL streptomycin).
Plasmid constructs. The HIV consensus clade C Envelope (Env) vaccine used in the
intradermal and intramuscular studies was generated based on the sequences retrieved from HIV
databases (http://www.hiv.lanl.gov). To produce a CCR5-tropic version of the HIV-1 envelope, six
important amino acids in V3 loop were designed according to the sequences of early transmitter
isolates. Six amino acids in V1 loop and three amino acids in V2 loop were deleted. The
cytoplasmic tail region was removed to promote higher expression of Env protein. The gp120/41
Env cleavage site was incorporated to promote proper folding of the synthetic Env protein. A
more efficient IgE leader sequence was added to the N-terminus of the gene. The transgene was
codon and RNA optimized for expression in human and mouse, synthesized by Genscript and
cloned into modified pVax1 mammalian expression vectors (Invitrogen) under the control of the
human cytomegalovirus (CMV) immediate-early promoter.
The DNA plasmids IDM2 and PB encode Leishmania Phosphoenolpyruvate carboxykinase
(PEPCK) and represent consensus sequences of PEPCK from a number of Leishmania parasite
strains. IDM2 is a consensus of PEPCK sequences from Leishmania parasites Infantum,
Donovani, Major, and Mexicana [Uniprot accession numbers A4I2Y7, E9BJI0, E9ADF9, E9AZ81].
PB is a consensus of PEPCK sequences from Leishmania species Panamensis and Braziliensis
[Uniprot accession numbers A0A088RTT4, A4HFV1]. A more efficient IgE leader sequence was
added to the N-terminal region of both genes. The transgenes were codon and RNA optimized for
expression in human and mouse, synthesized by Genscript and cloned into modified pVax1
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mammalian expression vectors (Invitrogen) under the control of the human cytomegalovirus
(CMV) immediate-early promoter.
The DNA plasmid used in the influenza study targets the hemagglutinin (HA) protein of H1N1
influenza A/PR/8/34 (PR8). The HA sequence was codon and RNA optimized for expression in
humans using GeneOptimizer sequence analysis software (Life Technologies), synthesized and
cloned by Aldevron into the pVax mammalian expression vector (Invitrogen) under the control of
the cytomegalovirus immediate-early promoter (CMV).
The DNA plasmid used in the Zika studies (ZIKV-prME) encodes full-length precursor membrane
(prM) plus Envelope/Env (E). A consensus strategy was used and the consensus sequences
were determined by the alignment of current Zika virus (ZIKV) prME protein sequences. A more
efficient IgE leader sequence was added to the N-terminal region of the gene. ZIKV-prME was
codon and RNA optimized for expression in humans, synthesized and cloned by Genscript into
pVax1 mammalian expression vector (Invitrogen) under the control of the cytomegalovirus
immediate-early promoter (CMV).
For the IL-36 cytokine studies, the full-length DNA plasmids encode murine IL-36 alpha, beta, and
gamma [Uniprot accession numbers Q9JLA2-1, Q9D6Z6-1, Q8R460-1]. A more efficient IgE
leader sequence was added to the N-terminal region of all three genes. The transgenes were
codon and RNA optimized for expression in human and mouse, synthesized by Genscript and
cloned into modified pVax1 mammalian expression vectors (Invitrogen) under the control of the
human cytomegalovirus immediate-early promoter (CMV). These full-length optimized IL-36
cytokine plasmids are known henceforth as opt-36α, opt-36β, and opt-36γ. Work by Towne et al.
has suggested the need for truncation of IL-36 cytokines nine amino acids N-terminal to a
conserved A-X-Asp motif, for full bioactivity. The second set of IL-36 plasmids was truncated
according to this data and they are henceforth known as opt-36αt, opt-36βt, and opt-36γt. These
inserts were modified as previously mentioned for full-length IL-36 plasmids.
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Leishmania parasites. Leishmania major parasites (WHO/MHOM/IL/80/Friedlin) parasites were
grown in Schneider’s insect medium (Invitrogen) supplemented with 20% heat-inactivated FBS, 2
mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Metacyclic enriched
promastigotes were used for infection.
Zika virus. Zika virus strain PR209 (Bioqual, MD) was amplified in Vero cells and stocks were
titred by standard plaque assay on Vero cells.
Western Blots. For transfection of PEPCK plasmids, HEK293T cells were grown to 80%
confluence in 6 well flat bottom tissue culture plates and transfected with 2 µg of HA tagged IDM2
or PB. The cells were collected 2 days after transfection, washed twice with PBS and lysed with
cell lysis buffer (Cell Signaling Technology, Danvers, MA). Gradient (4–12%) Bis-Tris NuPAGE
gels (Life Technologies, Carlsbad, CA) were loaded with transfected cell lysates and transferred
to PDVF membrane. The membranes were blocked in PBS Odyssey blocking buffer (LI-COR
Biosciences, Lincoln, NE, USA) for 1 h at room temperature. To detect plasmid expression, antiHA (A01244 Clone 5E11D8, GenScript) antibody was diluted 1:1000 and anti–β-actin antibody
diluted 1:5000 in Odyssey blocking buffer with 0.2% Tween 20 (Bio-Rad, Hercules, CA) and
incubated with the membranes overnight at 4 °C. The membranes were washed with PBST and
then incubated with the appropriate secondary antibody (goat anti-mouse IRDye680CW; LI-COR
Biosciences) at 1:15,000 dilution in Odyssey Blocking Buffer for 1 hour at room temperature. After
washing, the membranes were imaged on the Odyssey infrared imager (LI-COR Biosciences).

For transfection of opt-36αt, opt-36βt, and opt-36γt plasmids, U2OS cells were grown to 80%
confluence in 6 well flat bottom tissue culture plates and transfected with 2 µg of opt-36αt, opt36βt, and opt-36γt. The cells were collected 2 days after transfection, washed twice with PBS and
lysed with cell lysis buffer (Cell Signaling Technology, Danvers, MA). Gradient (4–12%) Bis-Tris
NuPAGE gels (Life Technologies, Carlsbad, CA) were loaded with transfected cell lysates and
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transferred to PDVF membrane. The membranes were blocked in PBS Odyssey blocking buffer
(LI-COR Biosciences, Lincoln, NE, USA) for 1 h at room temperature. To detect plasmid
expression, anti-HA (A01244 Clone 5E11D8, GenScript) antibody was diluted 1:1000 and anti–βactin antibody diluted 1:5000 in Odyssey blocking buffer with 0.2% Tween 20 (Bio-Rad, Hercules,
CA) and incubated with the membranes overnight at 4 °C. The membranes were washed with
PBST and then incubated with the appropriate secondary antibody (goat anti-mouse
IRDye680CW; LI-COR Biosciences) at 1:15,000 dilution in Odyssey Blocking Buffer for 1 hour at
room temperature. After washing, the membranes were imaged on the Odyssey infrared imager
(LI-COR Biosciences).
Immunofluorescence Assay (IFA). For the immunofluorescence assay, HEK293T cells were
grown in 6 well tissue culture slides and transfected with 2 µg of IDM2 or PB. Two days after
transfection, the cells were fixed with 4% paraformaldehyde for 15 min. Nonspecific binding was
then blocked with normal goat serum diluted in PBS at room temperature for 1 h. The slides were
then washed in PBS for 5 min and subsequently incubated with sera from IDM2 and PB
immunized mice at a 1:100 dilution overnight at 4 °C. The slides were washed as described
above and incubated with appropriate secondary antibody (goat anti-mouse IgG-AF488, Sigma,
St Louis, MO) at 1:200 dilutions at room temperature for 1 h. After washing, DAPI (Millipore
Sigma, Burlington, MA) was added to stain the nuclei of all cells following manufacturer’s
protocol. Wells were washed and maintained in PBS, and observed under a microscope (EVOS
Cell Imaging Systems; Life Technologies).

For IFA analysis of opt-36αt, opt-36βt, and opt-36γt, U2OS cells were grown in 6 well tissue
culture slides and transfected with 2 µg of HA-tagged opt-36αt, opt-36βt, and opt-36γt. Two days
after transfection, the cells were fixed with 4% paraformaldehyde for 15 min. Nonspecific binding
was then blocked with normal goat serum diluted in PBS at room temperature for 1 h. The slides
were then washed in PBS for 5 min and subsequently incubated with anti-HA antibody at a
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1:1000 dilution overnight at 4 °C. The slides were washed as described above and incubated with
appropriate secondary antibody (goat anti-mouse IgG-AF488, Sigma, St Louis, MO) at 1:200
dilutions at room temperature for 1 h. After washing, DAPI (Millipore Sigma, Burlington, MA) was
added to stain the nuclei of all cells following manufacturer’s protocol. Wells were washed and
maintained in PBS, and observed under a microscope (EVOS Cell Imaging Systems; Life
Technologies).

HIV gp120 protein binding ELISA. The ELISA was performed using 1 µg/ml HIV consensus C
gp120 (Immune Technology Corp., New York, NY) in PBS with 0.5% Tween 20 (PBS-T). After a
blocking step, serum from immunized mice was diluted to 1:50 and then 4-fold from there in 1%
FBS in PBS-T. Each sample was run in duplicate. After a 1-h incubation, plates washed and
incubated with goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) at a 1:5,000 dilution in 1%
FBS in PBS-T. Plates were then developed with SigmaFast OPD for 8-10 minutes and the
OD450 values were obtained.
Influenza hemagglutinin protein binding ELISA. Plates were coated with 1 µg/ml of
hemagglutinin ((H1N1) (A/New Caledonia/20/99) Immune Technology Corp.) in PBS. After a
blocking step, serum from immunized mice was diluted to 1:50 and then 4-fold from there in 1%
FBS in PBS-T. After a 1-h incubation, plates were washed five times with PBS-T washed and
incubated with goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) at a 1:5,000 dilution in 1%
FBS in PBS-T. Plates were then developed with SigmaFast OPD for 8-10 minutes, and the
OD450 values were obtained.
Influenza hemagglutinin avidity index ELISA. Plates were coated with 1 µg/ml of
hemagglutinin ((H1N1) (A/New Caledonia/20/99) Immune Technology Corp.) in PBS. After a
blocking step, serum from immunized mice was diluted to 1:50 and then 4-fold from there in 1%
FBS in PBS-T. After a 1-h incubation, plates were washed five times with PBS-T. Half of the wells
for each sample were incubated with denaturing reagent (8 M urea) for 5 min while the others
26

were incubated with PBS. Plates were washed and incubated with goat anti-mouse IgG-HRP
(Santa Cruz Biotechnology) at a 1:5,000 dilution in 1% FBS in PBS-T. Plates were then
developed with SigmaFast OPD for 8-10 minutes, and the OD450 values were obtained. The
avidity index was determined by dividing the OD450 values of the treated samples by those of the
untreated samples and multiplying by 100.

HIV ELISpot Assay. Precoated anti-IFN-γ ninety-six well plates (MabTech, Cincinnati, OH) were
used to quantify IFN-γ responses to vaccine. Single-cell suspensions of splenocytes were made
by homogenizing and processing the spleens through a 40 µm cell strainer. Cells were then reTM

suspended in ACK Lysing buffer (Gibco ) for 5 min to lyse red blood cells before two washes
with PBS and final re-suspension in RPMI complete media (RPMI 1640+10% FBS+1% penicillin–
streptomycin). Two hundred thousand splenocytes were added to each well and stimulated
overnight at 37°C in 5% CO2 with R10 (negative control), concanavalin A (3 µg/ml; positive
control), or specific HIV Env Clade C peptides (NIH AIDS Reagent Program). Peptide pools
consisted of 15-mer residues overlapping by 11 amino acids, representing the entire protein
consensus sequence of HIV-1 clade C were obtained from NIH AIDS Research and Reference
Reagent Program. The Env peptides were pooled at a concentration of 2 ug/ml/peptide into 4
pools as antigens for specific stimulation of IFN-γ release. After 18 hours of stimulation, the plates
were washed and developed following manufacturer’s protocol. The plates were then rinsed with
distilled water and dried at room temperature overnight. Spots were counted by an automated
ELISpot reader (Cellular Technology Ltd.).
Influenza ELISpot Assay. Precoated anti-IFN-γ ninety-six well plates (MabTech, Cincinnati, OH)
were used to quantify IFN-γ responses to vaccine. Single-cell suspensions of splenocytes were
made by homogenizing and processing the spleens through a 40 µm cell strainer. Cells were
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then re-suspended in ACK Lysing buffer (Gibco ) for 5 min to lyse red blood cells before two
washes with PBS and final re-suspension in RPMI complete media (RPMI 1640+10% FBS+1%
penicillin–streptomycin). Two hundred thousand splenocytes were added to each well and
stimulated overnight at 37°C in 5% CO2 with R10 (negative control), concanavalin A (3 µg/ml;
positive control), or 15 mer influenza hemagglutinin peptides overlapping by 11 amino acids
spanning the length of the consensus H1 hemagglutinin protein (GenScript). After 18 hours of
stimulation, the plates were washed and developed following manufacturer’s protocol. The plates
were then rinsed with distilled water and dried at room temperature overnight. Spots were
counted by an automated ELISpot reader (Cellular Technology Ltd.).
Leishmania ELISpot. Precoated anti-IFN-γ ninety-six well plates (MabTech, Cincinnati, OH)
were used to quantify IFN-γ responses to vaccine. Single-cell suspensions of splenocytes were
made by homogenizing and processing the spleens through a 40 µm cell strainer. Cells were
TM

then re-suspended in ACK Lysing buffer (Gibco ) for 5 min to lyse red blood cells before two
washes with PBS and final re-suspension in RPMI complete media (RPMI 1640+10% FBS+1%
penicillin–streptomycin). Two hundred thousand splenocytes were added to each well and
stimulated overnight at 37°C in 5% CO2 with R10 (negative control), concanavalin A (3 µg/ml;
positive control), or 15 mer IDM2 or PB peptides overlapping by 9 amino acids spanning the
entire length of the consensus protein (Genscript). After 18 hours of stimulation, the plates were
washed and developed following manufacturer’s protocol. The plates were then rinsed with
distilled water and dried at room temperature overnight. Spots were counted by an automated
ELISpot reader (Cellular Technology Ltd.).
Zika ELISpot Assay. Precoated anti-IFN-γ ninety-six well plates (MabTech, Cincinnati, OH)
were used to quantify IFN-γ responses to vaccine. Single-cell suspensions of splenocytes were
made by homogenizing and processing the spleens through a 40 µm cell strainer. Cells were
TM

then re-suspended in ACK Lysing buffer (Gibco ) for 5 min to lyse red blood cells before two
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washes with PBS and final re-suspension in RPMI complete media (RPMI 1640+10% FBS+1%
penicillin–streptomycin). Two hundred thousand splenocytes were added to each well and
stimulated overnight at 37°C in 5% CO2 with R10 (negative control), concanavalin A (3 µg/ml;
positive control), or 15 mer Zika peptides overlapping by 9 amino acids spanning the length of the
ZIKV-prME protein. After 18 hours of stimulation, the plates were washed and developed
following manufacturer’s protocol. The plates were then rinsed with distilled water and dried at
room temperature overnight. Spots were counted by an automated ELISpot reader (Cellular
Technology Ltd.).
Flow cytometry. For intracellular cytokine staining, two million cells were stimulated in 96-well
plates with overlapping peptide pools of HIV, influenza, Leishmania, or Zika protein as described
in the ELISpot section, media alone (negative control) and phorbol 12-myristate 13-acetate (PMA)
and ionomycin (BD Biosciences, San Jose, CA) (positive control) for 6 hours at 37 °C+5% CO2 in
the presence of GolgiPlug and GolgiStop

TM

(BD Biosciences). After 6 hours, cells were collected

and stained in FACS buffer with a panel of surface antibodies containing live dead eFluor V450,
FITC anti-CD4, Alexa Fluor 700 anti-CD44, and APC-Cy7 anti-CD8 for 30 min at 4 °C. Cells were
washed and then fixed with Foxp3/Transcription Factor Fixation/Permeabilization
(ThermoFischer Scientific) for 20 min at 4 °C. Cells were washed with Perm/Wash buffer before
intracellular staining with PE-Cy7 anti-IL-2, PerCP-Cy5.5 anti-CD3ε, PE anti- TNFα, and APC
anti-IFNγ for 1 hour at 4 °C. Cells were then washed with Perm/Wash buffer before suspension in
Perm/Wash buffer and acquisition on a BD LSRII. All results were analyzed using FlowJo

TM

v.10.0 (TreeStar).
Animals. Wildtype C57BL/6 and Balb-C mice were purchased from Jackson and Charles River
- -

Laboratories. IFNAR / mice lacking the IFN-α/β receptor were bred and housed at the Wistar
Institute Animal Facility. All animal housing and experimentation were in compliance with the

29

guidelines set by the NIH, the University of Pennsylvania School of Veterinary Medicine and the
Wistar Institutional Animal Care and Use Committee (IACUC).
Animal Injection Studies. For intramuscular (IM) vaccination studies, mice were administered a
30 µl injection of plasmid into the tibialis anterior (TA) muscle followed by in vivo electroporation
(EP) using a CELLECTRA adaptive constant current electroporation device (Inovio
Pharmaceuticals Inc.). For intradermal (ID) vaccination studies, mice were administered a 30 µl
injection of plasmid into the shaved abdominal flank skin to form a wheel (Mantoux injection)
followed by in vivo surface electroporation (SEP) (Inovio Pharmaceuticals Inc.). The epidermal
targeting surface EP (SEP) device consists of an electrode array made up from a 4x4 array of
gold-plated trocar needles of 0.43 mm diameter at a 1.5 mm spacing, which was pressed down
on the surface of the skin above the intradermal wheel in a manner in which all electrodes across
the array made contact with the surface of the skin.
Flank skin isolation: Flank skin was shaved using an electric trimmer equipped with a two-hole
precision blade (Wahl). A section of dermis was excised, and then minced with a sterile scalpel
blade into ∼2-mm sections. Flank sections were incubated in RPMI containing 250 µg/ml
Liberase TL for 120 min, with vortexing every 30 min. The resulting solution was passed through
a 40-µm cell strainer and resuspended in complete RPMI (cRPMI), which is supplemented with
10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 55 µM 2-mercaptoethanol.
Leishmania major Challenge Studies. L. major challenge studies were performed either oneweek post final vaccination (acute time point) or six weeks post-final vaccination (memory). Mice
were infected in the ear with 2 million L. major parasites. Immune mice group were infected with
L. major parasites 12 weeks before subsequent challenge. For ear preparation dorsal and ventral
layers of the infected ear were separated and incubated in RPMI (Invitrogen) with 250 µg/ml
Liberase TL (Roche, Basel, Switzerland) for 90 min at 37°C in 5% CO2. Ears were dissociated
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using a 40-µm cell strainer (BD) and resuspended in RPMI media containing 10% FBS. Parasite
burden from ear was calculated by serial 2-fold dilution in 96-well plates of G418 sulfate (CSM)
and incubated at 26°C. The number of viable parasites was calculated from the highest dilution at
which parasites were observed 7 days into culture.
− −

5

Zika Challenge Studies. IFNAR / mice were challenged with 1×10 PFU ZIKV-PR209 virus
two weeks post vaccination. Post challenge, the animals were weighed daily. In addition, they
were observed for clinical signs of disease twice daily (decreased mobility; hunched posture;
hind-limb knuckle walking (partial paralysis), paralysis of one hind limb or both hind limbs).
The criteria for euthanasia on welfare grounds consisted of 20% weight loss or prolonged
paralysis in one or both hind limbs.
Statistical Analysis. All graphs were prepared using GraphPad Prism 8 (GraphPad
Software). Survival data were expressed using Kaplan-Meier survival curves. A modified oneway ANOVA test with Tukey posthoc test was used to determine differences between
experimental groups.
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“Knowledge is power. Information is liberating. Education is the premise of progress, in every
society, in every family.” -Kofi Annan
Scene: Lumena, age 23 preparing to start the Gardasil regimen so she can be one less
woman who may have to deal with cervical cancer caused by HPV.

So what brings you in today for the Gardasil vaccine, Lumena? (nurse practitioner at Student
Health)
I keep seeing those “one less, one less, I want to be one less woman who will get cervical
cancer commercials” and I figure as much as I hate needles, I should probably get a vaccine
that will help prevent cancer. (Lumena, trying to act like the adult that I am)
Great. Let’s talk about what the vaccine is and some things you should be aware of. First, it is
a 3-dose vaccine…. (nurse practitioner making sure I am informed)
Wow…. 3 shots huh? (Lumena, crestfallen at the thought of coming back two more times for
this vaccine, wondering why so many shots can’t be one and done)
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CHAPTER 3- Designed DNA encoded IL-36 gamma acts as a potent molecular adjuvant
enhancing Zika synthetic DNA vaccine induced immunity and protection in a lethal challenge
model

Introduction
Identification of novel molecular adjuvants which can boost and enhance vaccinemediated immunity and provide dose sparing potential against complex infectious diseases and
for immunotherapy of cancer is likely to play a critical role in the next generation of vaccines.
Given the number of challenging targets for which no or only partial vaccine options exist,
adjuvants that can address some of these concerns are in high demand. Here, we report that a
designed truncated IL-36 gamma encoded plasmid can act as a potent adjuvant for several DNA
encoded vaccine targets including HIV, influenza, and Zika in immunization models. We further
show that the truncated IL-36 gamma (opt-36γt) plasmid provides improved dose sparing as it
boosts immunity to a suboptimal dose of a Zika DNA vaccine resulting in potent protection
against a lethal Zika challenge.
The most successful approach to controlling infectious diseases on a global scale has been
through vaccination. Vaccines have led to control, eradication or near eradication of several
infectious diseases, positively impacting both human longevity and the quality of life. However,
much work remains in this area. For many targets, current studies have suggested the need for
adjuvants, which can provide a number of benefits including improved vaccine effectiveness, as
discussed in several papers (Lahiri, Das, and Chakravortty 2008; Mosca et al. 2008; McKee,
Munks, and Marrack 2007). Adjuvants can boost overall immune responses to a specific vaccine,
thereby requiring either a lower dose or fewer immunizations, improving protection and
compliance as well as increasing the global vaccine supply for a particular product (Shah,
Hassett, and Brito 2017). Adjuvants can also help skew and tailor the immune response, which
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may be useful in scenarios where specific correlates of protection are understood (Podda 2001;
Khurana et al. 2010). Furthermore, adjuvants can boost immunity and shorten time to induce a
protective vaccine response in populations that traditionally have a difficult time mounting
protective responses, including the elderly and immunocompromised patients (Reed, Orr, and
Fox 2013). Alum, the most widely used adjuvant among current licensed vaccines, is well
documented to enhance humoral immunity (Wen and Shi 2016). Newer vaccine adjuvants
including MF59 and the Adjuvant Systems group 03 and 04 (AS03, AS04) have also been
licensed and shown to improve antibody responses to antigens as well as provide dose sparing
among other benefits for humoral responses (Wilkins et al. 2017). Shingrix, the latest vaccine
developed by GSK and approved to protect against reactivation of herpes zoster and postherpetic
neuralgia (shingles), is a recombinant vaccine made of glycoprotein E and ASO1 adjuvant, a
mixture of both MPL and QS-21, a saponin (Bharucha, Ming, and Breuer 2017). This vaccine
demonstrated an efficacy of over 95% against herpes zoster, with greater efficacy compared to a
live attenuated vaccine, ZostaVax, highlighting the impact that adjuvants can have on vaccine
outcomes. However, in spite of this success, there is still a major need in the clinic for adjuvants
that can improve CTL responses (Mosca et al. 2008). Some of the exciting work being done in
this field includes nontraditional adjuvants such as pathogen-recognition receptor (PRR) agonists,
liposomes, nanoparticles, and gene encoded cytokine adjuvants that can potentially jumpstart the
innate immune system and work in concert with the adaptive immune arm to drive lasting memory
against antigen.
The majority of the work done investigating PRR agonists has focused on Toll-like receptor
ligands (TLRs). TLRs are generally expressed by macrophages and dendritic cells that are
constantly surveying for conserved pathogen associated molecular patterns (PAMPs) derived
from microbes that breach initial physical barriers. Various TLR agonists have been studied as
potential adjuvants, including porin B (PorB) for TLR2, poly(I:C) for TLR3, and CpG for TLR9, with
studies showing enhanced immunity against a number of antigens (J.-K. Li et al. 2017; Tomai and
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Vasilakos 2012; Bhardwaj, Gnjatic, and Sawhney 2010). Unmethylated CpG DNA is recognized
by TLR9, and activates the innate arm of the immune system, which can help drive a Type 1 T
helper cell (Th1) response, critical for cellular mediated immunity. Studies have tested CpG as a
potential mucosal adjuvant, where the plasmacytoid dendritic cells (pDC) that they act on are
present in the mucosa (Iho, Maeyama, and Suzuki 2015). This represents an attractive target
given that the mucosa is a point of entry for many viral infections. However, much work is being
done to explore CpG as an adjuvant given that constant activation of TLR9 is thought to induce
autoimmunity in mice.
Costimulatory molecules, including 4-1BB and ICOS, have also been utilized as adjuvants for
vaccination. T cells need two signals in order to become activated: signal one, which is antigen
specific and involves the interaction between the T cell receptor and peptide major
histocompatibility complex (MHC), and signal two which is antigen nonspecific and involves the
interaction between costimulatory molecules on the APC and T cell. Without this second signal, T
cells will become anergized and will no longer become activated, even if they come into contact
with the antigen that they are specific for. The addition of these costimulatory molecules as
adjuvants to DNA vaccines represent an opportunity to enhance the interaction between the APC
and T cell, and potentially impact the magnitude of immune response. In a non-human primate
(NHP) simian immunodeficiency virus (SIV) study, macaques adjuvanted with 4-1BB showed
+

enhanced CD8 T cell responses compared to DNA vaccine only (Hokey et al. 2007; Hirao et al.
2011).
Chemokines, including CCL7, CCL4, and CCL19, are attractive as potential adjuvants due to their
inherent properties as chemotactic agents. In a DNA vaccine setting, these agents may be able to
draw in different cell populations that can expand the immune response to the delivered agent.
CCL4 has been shown to recruit dendritic cells, which may ultimately increase antigen
presentation, as well as natural killer cells and monocytes. CCL4 was able to adjuvant a DNA
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vaccine in a cancer mouse model, and partially ameliorate tumor burden (Nguyen-Hoai et al.
2016).
Cytokines, which are group of secreted proteins that mediate cross-talk between cells during
immune responses among other functions, have been widely explored as adjuvants for vaccines.
They play a critical role in inflammatory responses, and can both mediate or alleviate
inflammation depending on the class that they fall under. Proinflammatory cytokines include IL1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, TNF-α, and IFN-γ. Anti-inflammatory cytokines
include IL-37 and IL-38. Cytokines have been known to act as growth factors, mediate cellular
responses, drive antibody responses, and alarm the immune system of pathogens. Granulocytemacrophage colony-stimulating factor (GM-CSF), a white blood cell growth factor with strong
adjuvant properties, was one of the first cytokines that demonstrated a clear impact on DNA
vaccine-induced immunity. Mice immunized with GM-CSF along with a rabies DNA vaccine had
+

increased antibody production, stronger CD4 T cell responses and were protected after a lethal
challenge (Zhou et al. 2013).
+

+

IL-12 is a strong Th1 adjuvant that can expand CD8 and CD4 T cell responses. It has garnered
much attention in the field for its adjuvant properties in a number of preclinical models. In a nonhuman primate (NHP) study where monkeys were given an HIV-1 DNA vaccine and challenged,
primates adjuvanted with IL-12 showed increased cellular responses that corresponded with
better viremia control (Chong et al. 2007). Data from a clinical study showed that the inclusion of
plasmid IL-12 as part of an HIV synthetic DNA vaccine increased T cell magnitude and response
rates in people (Kalams et al. 2013).
Members of the IL-1 superfamily, the IL-36 family is made up of pro-inflammatory mediators
alpha, beta, gamma, as well as antagonist IL-36Ra (Catalan-Dibene, McIntyre, and Zlotnik 2018;
Clavel, Thiolat, and Boissier 2013; Dinarello 2013). This relatively novel cytokine family remains
poorly understood, although recent important studies have begun to shed light on their
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mechanism of action. Upon binding to the IL-36 receptor (IL-36R), and recruitment of the coreceptor accessory protein (IL-1RAcP), these cytokines activate the NF-κB/MAPK pathway
resulting in the stimulation of pro-inflammatory intracellular responses, whereas binding of the
antagonist, IL-36Ra, prevents recruitment of IL-1RAcP and does not lead to intracellular
+

response. IL-36R is primarily expressed on naïve CD4 T cells, but is also found on dendritic
cells, while the cytokines are expressed mainly in skin keratinocytes and epithelium, although
they are also expressed at low levels in the lung, kidneys, and intestine. Given reports of IL-36
beta’s ability to amplify Th1 responses (Vigne et al. 2012; 2011; Dietrich et al. 2016), we sought
to understand whether these cytokines could act as adjuvants for DNA vaccination models. Here,
we describe that a novel designed truncated IL-36 gamma (opt-36γt) as a co-formulated adjuvant
+

+

plasmid, boosts humoral as well as CD4 and CD8 T cell immunity against three model synthetic
DNA antigens including HIV Env, Influenza H1, and ZIKV-prME. Furthermore, opt-36γt enhanced
protection by improving both clinical symptoms and mortality against a Zika virus challenge and
provided significant dose sparing for the Zika vaccine as studied using a suboptimal vaccine dose
model. This not only supports the potential of opt-36γt as a gene adjuvant, but also highlights an
underappreciated area of importance for protective cellular immune responses in Zika virus
pathogenesis. Further investigation into opt-36γt as a potential new adjuvant for enhancing
immunity against vaccine antigens is warranted.
Results
Truncation of IL-36 beta enhances immune responses against HIV DNA vaccine. While the
IL-36 family was discovered in 1999, members of this family remain poorly understood and
continue to be investigated. In the initial studies of their biology, large quantities of IL-36 ligands
were needed, in greater excess than those traditionally used for cytokines, to observe their
activity. Given the fact that many of the IL-1 family members including IL-1α, IL-1β, IL-18, and
IL-33 require proteolytic cleavage to gain activity, it was not altogether surprising that recent
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reports demonstrated the need for N-terminal residue truncation to achieve full bioactivity of IL-36
ligands (Towne et al. 2011). The lack of caspase cleavage motifs in the N-terminus of the
cytokines has confounded the field, however recent studies suggested the role of neutrophil
proteases in activating IL-36 cytokines (Henry et al. 2016). In our studies, we examined whether
truncation was important for an IL-36 in vivo produced gene adjuvant to impact immune profile of
DNA vaccine antigens in an in vivo DNA vaccine model system (Figure 3). We chose to initially
start our studies with IL-36 beta, as IL-36 beta has been reported to amplify Th1 responses,
making it a potential cellular adjuvant candidate. We designed two DNA constructs encoding
either full length (opt-36β) or truncated (opt-36βt) IL-36 beta for these comparative studies. We
added a highly efficient IgE leader sequence to both of the sequences as well as RNA and codon
optimized them in order to enhance protein expression (Figure 4). We then immunized C57BL/6
(B6) (n=5) mice with 2.5 µg of HIV Env DNA alone or with 11 µg opt-36β or opt-36βt, three times
at three-week intervals using the 3P electrode driven by an adaptive electroporation CELLECTRA
(EP) device. Spleens were harvested ten days post-final vaccination for analysis of antigen
specific responses (Figure 5). We observed a significant increase in the number of antigen
+

specific CD4 T cells that secreted IFN-γ and TNF-α in the animals whose vaccine included opt36βt compared to opt-36β (Figure 6). There was a trend towards a similar pattern of
+

+

enhancement for the antigen induced CD8 T cell responses, but in contrast to the CD4 T cell
responses, this did not reach significance. A dosing study was next performed, focusing primarily
on T cell induction to determine the optimal dose of opt-36βt (Figure 7). We found no significant
difference in T cell response with higher doses and, in fact, there appeared to be a trend towards
decreased immune response at the 30µg dose of opt-36βt. Going forward, we maintained our
established dose of 11µg dose for adjuvant plasmid for the remainder of the studies.
Expression of all three truncated IL-36 cytokines. Given the immune response enhancement
observed with truncation of IL-36 beta, we next examined the rest of the IL-36 family as truncated
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cytokines. In this regard, even less is known about IL-36 alpha or gamma compared to beta, so
we wanted to evaluate the immune responses in mice adjuvanted with each of the three
cytokines in comparative studies. Truncated IL-36 alpha (opt-36αt) and IL-36 gamma (opt-36γt)
were designed and modified as described for opt-36βt (Figure 8). Construct expression in vitro
was confirmed by Western blot and IFA (Figures 9 and 10).
Opt-36βt and opt-36γt maintain vaccine-induced responses at a memory time point. A
major concern in the vaccine field is the generation of candidates that can provide durable, longterm immune responses. Generally, people are immunized to prevent future illness, and so
special consideration must be taken into account for the durability of induced immune responses.
With this in mind, we examined whether immune responses following DNA vaccination would be
maintained into memory. B6 mice (n=5/group) were immunized using 2.5 µg of HIV Env DNA
alone or formulated with 11 µg of opt-36αt, opt-36βt, or opt-36γt three times at three-week
intervals with CELLECTRA 3P electroporation (EP). Spleens were harvested 50 days post-final
vaccination to analyze antigen specific responses at a memory time point (Figure 11). A
quantitative ELISpot was performed to determine the number of Env specific IFN-γ secreting T
cells that responded to vaccination. We observed that mice immunized with the HIV vaccine
alone produced an average of 775 spot forming units (SFU)/million splenocytes, while mice
adjuvanted with opt-36αt, opt-36βt, and opt-36γt had an average of 1242, 1460, and 1610
SFU/million splenocytes, respectively, supporting a potently enhanced cellular response to the
vaccine was driven by the adjuvants. Similar to the results observed at an acute time point, we
+

found that mice adjuvanted with opt-36βt showed a significant increase in the percent of CD4 T
cells that expressed IFN-γ and TNF-α, compared to vaccine only (Figure 12). Interestingly, mice
+

adjuvanted with opt-36γt showed a 3-fold enhancement in the percent of vaccine specific CD8 T
cells, which expressed IFN-γ and TNF-α. We further observed that mice vaccinated with vaccine
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and opt-36γt had a significant increase in the percent of CD107a IFN-γ CD8 T cells, suggesting
the cytolytic potential of these cells (Figure 13).
Opt-36γt boosts humoral responses in an influenza DNA vaccine model. We next sought to
extend this finding to additional DNA vaccine antigens. We studied opt-36αt, opt-36βt, and opt36γt’s ability to impact immune responses driven by an HA1 influenza DNA vaccine. Given the
potency of the adjuvant response in the previous HIV Env studies, we focused on a two-dose
regimen to evaluate the vaccine-induced immune response in a dose-sparing model. Balb/C mice
(n=5/group) were immunized two times at two-week intervals with either 1 µg of HA1 DNA alone
or 1 µg of HA1 and 11 µg of opt-36αt, opt-36βt, or opt-36γt followed by in vivo EP. We observed
that both opt-36βt and opt-36γt significantly enhanced cellular responses compared to the low
dose vaccine alone, 10 days post final immunization (Figure 14). We observed increased cellular
responses in mice adjuvanted with opt-36αt, however this was not as pronounced as the
responses seen with the other two ligands. As antibodies are known to be critical for prevention
of influenza infection, we studied the binding antibody response generated post vaccination. Opt36γt elicited significant higher endpoint binding titers compared naïve mice (Figure 15). We
further examined the quality of these antibodies, by performing an ELISA based avidity test to
examine strength of binding to a HA1 influenza protein (Figure 16). Interestingly, we observed
that only mice adjuvanted with opt-36γt had higher antibody binding and maintained avidity while
opt-36αt adjuvanted mice had lower antibody binding and avidity compared to vaccine alone and
opt-36βt adjuvanted mice had higher antibody binding but lower antibody avidity. These data
support the induction of improved humoral responses by opt-36γt, and potentially suggest a role
for T follicular helper cells (Tfh), which are important for refining the antibody response over time.
We also examined the isotypes of the antibodies generated post vaccination in order to assess
potential Fc receptor mediated immune response such as antibody dependent cellular cytotoxicity
(ADCC), but did not observe significant isotype switching between the groups (Figure 17).
40

Opt-36γt improves cellular responses induced by a nonprotective dose of Zika DNA
vaccine. Based on the data generated in the two DNA vaccine models above, we focused on
studying opt-36γt in combination with a DNA vaccine against Zika virus and observing how
adjuvanted vaccine-induced immune response impacted challenge outcome. This model allowed
us to confirm the relevance of the improved immunity and dose sparing potential driven by the
opt-36γt adjuvant. Previous murine studies have described a protective dose as 25 µg, however a
- -

lower dose is necessary to observe adjuvant impact. We immunized IFNAR / mice (n = 5-6
mice/group) once with an exceptionally low dose (0.5 µg) of ZIKV-prME DNA vaccine alone or a
combination of vaccine and opt-36γt. Two weeks following vaccination, we harvested spleens
and blood. We observed that mice immunized with low dose vaccine only did not generate
significant IFN-γ ELISpot responses, but the combination of the vaccine and opt-36γt drove
cellular response, resulting in 700 SFU/million splenocytes, similar to the magnitude of response
observed in previous studies when mice are immunized with 25 µg of ZIKV-prME vaccine alone
(Figure 18). Through intracellular cytokine staining measurements, we observed that mice
+

adjuvanted with opt-36γt exhibited increased IFN-γ and TNF-α expressing CD4 T cells as well as
+

IFN-γ expressing CD8 T cells compared to the vaccine only treated mice (Figure 19). Overall
antibody responses were very low in all groups, suggesting a need for additional vaccine boosts
or higher vaccine doses to further characterize the humoral immunity induced in this model
(Figure 20).
Opt-36γt codelivery protects mice against Zika challenge. In order to assess whether the
enhanced immune responses observed were protective, we repeated the study and this time
- -

performed a challenge using IFNAR / mice (n = 12-14/ group) with a lethal dose of a validated
Zika virus stock, strain PR 209. Challenge was performed two weeks after an immunization with
either 0.5 µg of ZIKV-prME alone or in combination with 11 µg of opt-36γt. The animals were
followed for two weeks post challenge. One of the main side effects of Zika challenge typically
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observed in this mouse strain is weight loss. Significant weight loss was observed in both the
naïve and mice immunized with the suboptimal dose of the ZIKV-prME vaccine alone
demonstrating substantial morbidity from the challenge (Figure 21). Naïve mice appeared to be
the most impacted, with many mice losing up to 20% of their starting body weight. The low dose
vaccine only group fared a bit better compared to the naive but still lost a considerable amount of
weight. Strikingly, mice immunized with ZIKV-prME in combination with opt-36γt were protected
against weight loss, gaining weight during the course of the study. Additionally, mice were
monitored for clinical symptoms during the challenge (Figure 22). Mice in both naïve and vaccine
only groups became progressively sicker (i.e. hunched posture and paralysis of hind limbs)
between days 5 and 7. However, the adjuvanted mice remained healthy and showed no sign of
disease following challenge. As animals succumb to disease they are sacrificed at predefined
humane endpoints. Dramatically, mice immunized with ZIKV-prME and opt-36γt exhibited a
robust 92% survival rate, compared to 28% for mice immunized with the ZIKV-prME only and
13% for naïve mice (Figure 23), illustrating the significant benefit of the opt-36γt adjuvant in the
context of this challenge model.

Discussion
While the IL-36 cytokine family was first discovered nearly two decades ago, it is only recently
that roles for these cytokines are beginning to be elucidated. The IL-36 family, members of a
larger proinflammatory IL-1 family, has been primarily implicated for their potential role in pustular
psoriasis and inflammation of the skin and joints (Johnston et al. 2017; Ding et al. 2017; Foster et
al. 2014; Kanazawa et al. 2013). Dysregulation of the natural IL-36 receptor antagonist or
overexpression of IL-36 in the skin has been implicated in a number of skin diseases and
conditions. However, some of these proinflammatory properties have also piqued the scientific
community’s interest regarding some of the other roles that these cytokines might play. Following
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reports that IL-36 beta could amplify Th1 responses in CD4 T cells, a number of studies have
shown the induction of IL-36 cytokine expression, especially IL-36 gamma, in response to
infections including pneumonia, herpes simplex virus (HSV), and candidiasis, suggesting that IL36 cytokines may play a significant role in host immunity (Verma et al. 2018; P. Wang, Gamero,
and Jensen 2019; Winkle, Throop, and Herbst-Kralovetz 2016; X. Wang et al. 2015a; Kovach et
al. 2017).
To our knowledge, this is the first study to compare the effects of all three truncated IL-36
cytokines in a vaccination model. In these studies we provide additional insight into the ability of
truncated IL-36 gamma’s (opt-36γt) ability to boost immune responses using three DNA vaccine
antigens. As previously demonstrated by Towne et. al, we found that truncation of the IL-36
cytokines nine amino acids at the N-terminal region was critical for their activity to enhance
vaccine-induced immune responses. For future investigations of IL-36 cytokines in protective
immunity studies, the truncated forms of these cytokines will almost certainly be necessary to
exploit their full potential.
In the DNA vaccine models we tested, we found that mice immunized with opt-36βt and opt-36γt
were both able to enhance vaccine-induced cellular immune responses. However, where opt-36βt
+

+

+

was able to significantly increase the number of antigen-specific IFN-γ and TNF- α CD4 T cells,
+

+

opt-36γt significantly increased the number of antigen-specific IFN-γ , TNF-α , and CD107a

+

+

CD8 T cells, suggesting an impact of opt-36γt to improve cytolytic activity of these cells. Further
work must be done to understand the differences between the two cytokines’ seemingly
preferential action on various cell compartments. Regarding humoral immunity in this model, we
found that opt-36γt was able to increase antibody-binding titers, while opt-36βt appeared to either
suppress the antibody response or induce antibodies that have weak avidity. Thus, in our models,
opt-36γt can improve both arms of immune response, which is likely important for many of the
challenging disease targets that remain. Furthermore, we found that the synergy of a non43

protective dose of Zika DNA vaccine with opt-36γt was able to protect mice against a lethal Zika
challenge, highlighting the potential of opt-36γt to affect challenge outcome and drive protection.
A caveat to our studies on opt-36γt is that although opt-36γt was able to enhance antibody
binding in the HIV and influenza DNA models, overall humoral responses in the Zika DNA model
were very low. This suggests that there may be a minimum dose of vaccine required to enhance
antibody responses and/or that there may be differential activities of these cytokines depending
on the antigen, and further work to investigate these conditions are underway. Although the
antibodies generated after vaccination were low, the addition of opt-36γt was still able to protect
against Zika challenge, highlighting the importance of cellular immunity in this model, even in the
absence of a robust antibody response.
There is still much work to be done to fully understand the roles that the IL-36 cytokines play
under both homeostatic and pathologic conditions in the host immune system. Multiple studies in
mice have shown that the IL-36 cytokines may have distinct functions in response to different
inflammatory stimuli. Understanding how opt-36βt and opt-36γt may exert their activities on
different cell populations and against additional vaccine targets will be important for further
+

+

harnessing their potential. Given their ability to enhance CD4 and CD8 T cell responses, opt36γt and opt-36βt look especially promising for disease models in which cellular responses are
+

important, such as cancer where driving CD8 immunity is important to clear tumors. Studies
examining the effects of opt-36γt on driving tumor-infiltrating lymphocytes (TILS) would be
relevant. Work by Wang et al has demonstrated that tumor growth was significantly inhibited in
B16 melanoma IL-36 expressing cells compared to control B16 cells that did not express IL-36
gamma in mice (X. Wang et al. 2015b). Wang et al. also found that IL-36 gamma could promote
+

early activation and expansion of naïve CD8 T cells, in line with what we have observed in our
DNA vaccine models.
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The induction of higher binding antibodies while maintaining avidity by opt-36γt as seen in the
influenza studies may have a critical role in diseases in which highly refined and mature
antibodies are important. As more emphasis is being focused to identify immunogens that can
elicit broadly neutralizing antibodies (bNabs) for HIV and Influenza, adjuvants that can further
refine the antibody response may prove important. Future studies that hone in on the effects of
IL-36 cytokines, especially IL-36 gamma, on the T cell populations that support enhanced
antibody affinity such as T follicular helper cells (Tfh), will help to further characterize the immune
responses elicited during vaccination, and also deepen the understanding of the IL-36 cytokine
family as well. In addition, deeper characterization of the antibodies generated with IL-36
adjuvanted vaccination, such as complementarity-determining region (CDR) sequencing,
especially for the CDR3 region where the most sequence variability exists, will likely further
broaden the understanding of these cytokines’ activities, especially for IL-36 gamma.
Although there appears to be a deleterious effect on skin health when IL-36 signaling is left
unchecked, localized controlled and likely transient delivery of opt-36γt as an adjuvant during
intradermal vaccination could enhance vaccine responses and recruitment of cells to the site of
infection. This could be especially important for infectious diseases that breach the skin’s natural
barrier including herpes, malaria, and Leishmania among others. As the largest organ in the
human body, with a rich source of antigen presenting cells (APCs) including Langerhans cells, as
well as nearly 20 billion T cells, the skin is a particularly attractive site to administer an opt-36γt
adjuvanted vaccine. Enhanced CTL responses in the skin can help control the spread of an
infection before it is able to disseminate to other locations in the body, while greater antibody
responses may help with prevention of infection. Studies that examine the delivery of opt-36γt in
the skin compared to intramuscular delivery may shed light on another route to impact vaccine
immune outcome as well as protection against infection.
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As the global population and the demand for vaccines increase worldwide, the need to maximize
immune responses while minimizing the effective dose necessary to induce protective responses
will continue to grow to further control costs. Opt-36γt, which has shown adjuvant activity as a
dose sparing adjuvant, may represent a potential avenue to meet some of these demands. The
work presented in these studies in addition to all the amazing work being done in the vaccine field
has reinforced the need for more focus on developing new adjuvants that work in a variety of
settings for other vaccine platforms and generating their adjuvant effects through unique
mechanisms of action.
*Modified from: Louis L, Wise MC, Choi H, Muthumani K, Villarreal DO, Weiner DB. Designed
DNA encoded IL-36 gamma acts as a potent molecular adjuvant enhancing Zika synthetic DNA
vaccine induced immunity and protection in a lethal challenge model. Vaccines. 2019; 7(2) 42
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31
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Figure 4. IL-36 beta sequence design.
These maps illustrate the design if the optimized IL-36 beta constructs. Opt-36β is the full length
beta cytokine that has been RNA and codon optimized and is under the control of the immediate
early cytomegalovirus (CMV) promoter. Opt36βt is the truncated form of IL-36 beta, with the first
30 amino acids removed. An efficient IgE leader sequence was added to the beginning of both
sequences, and both sequences were inserted into a pVax backbone.
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Day
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Immunization 3
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52

Groups (n = 5 mice per group) Right TA
1) Naive
2) Env only
3) Env + opt-36β
4) Env + opt-36βt
Figure 5. Delivery of full length vs truncated IL-36 beta.
C57BL/6 mice (n= 5 mice/group) received an intramuscular DNA injection and EP of either 2.5 µg
of HIV Env vaccine alone, 2.5 µg of HIV Env vaccine and 11µg of opt-36β (full length optimized IL-36
beta), or 2.5 µg of HIV Env vaccine and 11µg of opt-36βt (truncated optimized IL-36 beta), three times
at three week intervals in the tibialis anterior muscle. Spleen and blood were harvested 10 days after
the final immunization.
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Figure 6. Vaccine induced CD4 and CD8 IFN-γ and TNF-α T cell responses post opt-36β or
opt-36βt codelivery
C57BL/6 mice (n = 5 mice/group) received an intramuscular DNA injection and EP of either 2.5 µg of
HIV Env vaccine alone, 2.5 µg of HIV Env vaccine and 11µg of opt-36β (full length optimized IL-36
beta), or 2.5 µg of HIV Env vaccine and 11µg of opt-36βt (truncated optimized IL-36 beta), three times
+
+
at three week intervals in the tibialis anterior muscle. Antigen specific CD4 and CD8 T cell
responses measured by intracellular cytokine staining 10 days after final immunization. Error bars
represent standard error of mean. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001
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Figure 7. Vaccine induced CD4 and CD8 IFN-γ and TNF-α T cell responses post dosing study
of opt-36βt
C57BL/6 mice (n = 5 mice/group) received an intramuscular DNA injection and EP of either 2.5 µg of
HIV Env vaccine alone, 2.5 µg of HIV Env vaccine and 11µg of opt-36βt (truncated optimized IL-36
beta), 2.5 µg of HIV Env vaccine and 20µg of opt-36βt, or 2.5 µg of HIV Env vaccine and 30µg of opt+
+
36βt three times at three week intervals in the tibialis anterior muscle. Antigen specific CD4 and CD8
T cell responses measured by intracellular cytokine staining 10 days after final immunization. Error
bars represent standard error of mean. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001
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Figure 8.Truncated IL-36 alpha and gamma sequences.
Figure 8. Truncated IL-36 alpha and gamma sequences
Truncated IL-36 beta cytokine sequence. The sequences represent full length sequences that
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Figure 9. Optimized IL-36 cytokine constructs express in vitro
These maps illustrate the design of C terminus HA-tagged optimized truncated IL-36 alpha, beta, and
gamma constructs. Later studies with opt-36αt, opt-36βt, and opt-36γt were performed with plasmids
without an HA tag. The cytokines have been RNA and codon optimized and are under the control of
the immediate early cytomegalovirus (CMV) promoter. The beginning of each sequence 9 amino
acids N-terminal to a conserved anchoring motif was removed. Western blot anaylsis of opt-36αt, opt36βt, and opt-36γt transfected U2OS lysates, separated by SDS-page under reducing conditions.

53

DAPI

Opt-36t

Merge

pVax empty

Opt-36αt

Opt-36βt

Opt-36γt

Figure 10. Immunofluorescence expression of HA-tagged opt-36αt, opt-36βt, and opt-36γt
Immunofluorescence assay (IFA) analysis of HA-tagged opt-36αt, opt-36βt, and opt-36γt transfected
U2OS cells.
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Figure 11. IFN-γ T cell response post opt-36t codelivery immunization at a memory timepoint
C57BL/6 mice ( n = 3-5 mice/group) received an intramuscular DNA injection and EP of either 2.5 µg
of HIV Env vaccine alone, 2.5 µg of HIV Env and 11µg of opt-36αt, 2.5 µg of HIV Env and 11µg of opt36βt, or 2.5 µg of HIV Env and 11µg of opt-36γt three times at three week intervals in the tibialis
anterior muscle. ELISpot analysis of IFN-γ responses 50 days after final immunization.
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Figure 12. Vaccine induced CD4 and CD8 T cell responses at memory timepoint
C57BL/6 mice ( n = 3-5 mice/group) received an intramuscular DNA injection and EP of either 2.5 µg
of HIV Env vaccine alone, 2.5 µg of HIV Env and 11µg of opt-36αt, 2.5 µg of HIV Env and 11µg of opt36βt, or 2.5 µg of HIV Env and 11µg of opt-36γt three times at three week intervals in the tibialis
+
+
anterior muscle. Antigen specific CD4 and CD8 T cell responses measured by intracellular cytokine
staining 50 days after final immunization. Error bars represent standard error of mean. * p < 0.05, ** p
< 0.005, *** p < 0.0005, **** p < 0.0001
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Figure 13. Vaccine induced CD107a T cell responses at memory timepoint following opt-36t
codelivery
C57BL/6 mice ( n = 3-5 mice/group) received an intramuscular DNA injection and EP of either 2.5 µg
of HIV Env vaccine alone, 2.5 µg of HIV Env and 11µg of opt-36αt, 2.5 µg of HIV Env and 11µg of opt36βt, or 2.5 µg of HIV Env and 11µg of opt-36γt three times at three week intervals in the tibialis
+
+
anterior muscle. Antigen specific CD107a CD8 T cell responses measured by intracellular cytokine
staining 50 days after final immunization. Error bars represent standard error of mean. * p < 0.05, ** p
< 0.005, *** p < 0.0005, **** p < 0.0001
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Figure 14. Vaccine induced cellular IFN-γ T cell responses following opt-36t codelivery
Balb/C mice ( n = 5 mice/group) received an intramuscular DNA injection and EP of either 1µg of
Influenza HA1 vaccine alone, 1 µg of Influenza HA1 and 11µg of opt-36αt, 1µg of HA1 and 11µg of
opt-36βt, or 1 µg of HA1 and 11µg of opt-36γt two times at two week intervals in the tibialis anterior
muscle. ELISpot analysis of IFN-γ responses 14 days after final immunization.
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Figure 15. Opt-36γt enhances antibody response against influenza hemagglutinin protein
Antibody binding analysis of sera from mice immunized twice at two week intervals with HA1 only (1
µg), HA1 (1 µg) and opt-36αt (11 µg), HA1 (1 µg) and opt-36βt (11 µg), and HA1 (1 µg) and opt-36γt
(11 µg). ELISA samples run in duplicate. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001

59

0.8
0.8

0.6

HA1
HA1 + urea

0.4

OD 450

OD 450

0.6

0.2

HA1 + opt-36αt
HA1 + opt-36αt + urea

0.4

0.2

0.0
101

102

103

104

105

0.0
101

106

102

103

104

105

106

Serial Dilutions

Serial Dilutions

1.5

1.5

1.0

HA1 + opt-36βt
HA1 + opt-36βt + urea

OD 450

OD 450

1.0

0.5

HA1 + opt-36γt
HA1 + opt-36γt + urea
0.5

0.0
101

102

103

104

105

0.0
101

106

Serial Dilutions

102

103

104

105

106

Serial Dilutions

Avidity Index 1:50

100
80
60
40
20
0

HA1

HA1 + opt-36αt HA1 + opt-36βt HA1 + opt-36γt

Figure 16. Opt-36γt maintains antibody avidity against influenza hemagglutinin protein after
denaturing treatment
Antibody binding analysis of urea treated sera from Balb/C mice (n = 5) immunized twice at two week
intervals with HA1 only (1 µg), HA1 (1 µg) and opt-36αt (11 µg), HA1 (1 µg) and opt-36βt (11 µg), and
HA1 (1 µg) and opt-36γt (11 µg). ELISA samples run in duplicate. Avidity index calculated by dividing
OD450 values of treated samples by OD450 values of untreated samples and multiplying by 100.
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Figure 17. Antibody isotypes induced post opt36t delivery
Isotype binding analysis of sera from mice immunized twice at two week intervals with HA1 only (1
µg), HA1 (1 µg) and opt-36αt (11 µg), HA1 (1 µg) and opt-36βt (11 µg), and HA1 (1 µg) and opt-36γt
(11 µg).
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Figure S2
A ELISA analysis measuring isotype binding antibody production (measured by OD 45
immunized twice two weeks apart with 1 µg of H1 DNA plasmid or H1 DNA plasmid an
antibodies generated were analyzed with sera from animals post final vaccination. B Ig
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Figure 18. Opt-36γt enhances vaccine specific IFN-γ cellular responses against Zika prME
vaccine
IFNAR -/- mice (n = 5-6 mice/group) were immunized once with either Zika prME vaccine alone (0.5
µg) or Zika prME (0.5 µg) and opt-36γt (11 µg). ELISpot analysis of IFN-γ cellular responses 14 days
after immunization.
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Figure 19. Opt-36γt enhances vaccine specific CD4 and CD8 T cell responses against prME
IFNAR -/- mice (n = 5-6 mice/group) were immunized once with either Zika prME vaccine alone (0.5
+
+
µg) or Zika prME (0.5 µg) and opt-36γt (11 µg). Antigen specific CD4 and CD8 T cell responses
measured by intracellular cytokine staining 14 days after DNA injection and EP. Error bars represent
standard error of mean. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001
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Figure 20. Single low dose of Zika prME vaccine does not induce antibody response
Antibody binding analysis of sera from IFNAR -/- mice (n = 5-6 mice/group) immunized once with
either Zika prME vaccine alone (0.5 µg) or Zika prME (0.5 µg) and opt-36γt (11 µg). ELISA samples
run in duplicate.
Figure S4
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Figure 21. Opt-36γt adjuvanted mice maintain weight following Zika virus challenge
IFNAR-/- mice (n= 12-14 mice/group) were immunized once with either Zika prME vaccine alone (0.5
µg) or Zika prME (0.5 µg) and opt-36γt (11 µg) and challenged 14 days later with mouse adapted Zika
virus strain, PR 209. Average body weight measurements of IFNAR -/- mice over the course of 14
days following challenge reported.
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Figure 22. Opt-36γt enhances protection against clinical symptoms following Zika virus
challenge
IFNAR-/- mice (n= 12-14 mice/group) were immunized once with either Zika prME vaccine alone (0.5
µg) or Zika prME (0.5 µg) and opt-36γt (11 µg) and challenged 14 days later with mouse adapted Zika
virus strain, PR 209. Mice were monitored for 14 days following Zika virus challenge, and clinical
symptoms due to challenge are depicted above for days 5-7.
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Figure 23. Codelivery of opt-36γt boosts overall survival following Zika virus challenge
IFNAR-/- mice (n= 12-14 mice/group) were immunized once with either Zika prME vaccine alone (0.5
µg) or Zika prME (0.5 µg) and opt-36γt (11 µg) and challenged 14 days later with mouse adapted Zika
virus strain, PR 209. Mice were monitored for 14 days following Zika virus challenge for survival rates
and were euthanized at predefined humane endpoints of either 20% loss of body weight or prolonged
hind limb paralysis. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001

67

“When I was a child, I spoke as a child, I understood as a child, I thought as a child; but when I
became a man, I put away childish things.” 1 Corinthians 13:11, The Holy Bible

Scene: Lumena, age 28, realizing that she can get the updated Gardasil vaccine that
protects against 9 strains of HPV, compared to the four strains in the original vaccine she
took 5 years earlier at Student Health.

Student Health now administers Gardasil9 for students up to the age of 45? (Lumena reading
Student Health’s website and realizing that she can get the updated Gardasil vaccine at no extra
cost since the FDA approved the vaccine for a wider range of ages)
Oh my goodness, I gotta go set up my appointment now. I need all the protection I can get! Why
have protection against 4 strains when you can have protection against 9? (Lumena furiously
logging into the student health portal to set up an appointment to start the vaccine course)
Mommy, can you believe I can get this updated version of the vaccine, for FREE? I wish this was
approved earlier so that I would have gotten the Gardasil 9 regimen from the start…(Lumena
chatting with her mom about this vaccine)
Man, times change! I remember when I had to drag you to the doctor to scream through your
shots, and now you are actively seeking them out! (Lumena’s mom still in amazement every time
she willingly gets her vaccines.)
This life is hard, and I want to cover all the bases I can! (Lumena showing her mom the progess!)

68

CHAPTER 4- Intradermal synDNA vaccination generates Leishmania specific T cells in
the skin and protection against Leishmania major

Introduction
Vaccination remains one of the greatest medical breakthroughs in human history, and has
resulted in near eradication of many former lethal diseases in many countries including the
complete eradication of smallpox. However, there remain a number of diseases for which there
are no or only partially effective vaccines. There are numerous hurdles in vaccine development,
of which knowing the appropriate immune response to target is one of them. Recently, tissue
resident T cells have been shown to mediate high levels of protection for several infections,
although the best ways to induce these cells is still unclear. Here we compare the ability to
generate skin resident T cells in sites distant from the immunization site following intramuscular
and intradermal injection using optimized SDNA vaccines. We observed that mice immunized
intradermally with a synthetic consensus DNA HIV Envelope vaccine by electroporation (EP) are
better able to maintain durable antigen specific cellular responses in the skin compared to mice
immunized by the intramuscular route. We extended these studies by delivering a synDNA
vaccine encoding Leishmania Glycosomal Phosphoenolpyruvate Carboxykinase (PEPCK) by EP,
and again found that the intradermal route was superior to the intramuscular route for generating
skin resident PEPCK specific T cells. When challenged with Leishmania major (L. major)
parasites, we observed that mice immunized intradermally exhibited significant disease control,
while mice immunized intramuscularly did not. The protection seen in intradermally vaccinated
mice supports the viability of this platform to generate skin resident T cells, but and promote
durable protective immune responses at relevant tissues sites.
The most successful approach to controlling infectious diseases is the development of protective
vaccines, but unfortunately there remain several diseases for which no vaccines are available.
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Resolving this deficit will require identifying the immune responses that provide protection, and
then understanding how best to generate them. Recent studies with several diseases have
reported that T cells residing in the tissues, resident memory T cells or Trm cells (Gaide et al.
2015; Mackay et al. 2012; Jiang et al. 2012), can often provide greater protection than those that
are circulating alone, although how to best generate Trm cells through a vaccine remains poorly
understood. For example, some studies suggest that intradermal immunizations or skin
scarification may be particularly effective at generating skin Trm cells, while other studies are less
clear on this population’s importance (Gray, Westerhof, and MacLeod 2018; Iborra et al. 2016;
Takamura 2018). We wanted to address this issue in part by comparing the generation of skin
resident T cells and protection against cutaneous Leishmaniasis following DNA immunizations via
the intramuscular route, most often used for currently approved vaccines, and the intradermal
route.
Leishmania infection occurs in over 88 countries, with an estimated 12 million people currently
infected and over 350 million people at risk (Ponte-Sucre et al. 2017; Sundar and Singh 2014).
The parasite is spread by the sand fly during the infective stage, metacyclic promastigotes, during
a blood meal and is phagocytized by macrophages at the site of injection. The parasite then
differentiates to the amastigote stage, multiplies, and infects other cells and tissues depending on
the specific strain. The cycle is complete when a sandfly feeds on an infected host and picks up
the amastigotes where they differentiate into promastigotes in the gut. Leishmania infection
primarily impacts people in resource strained settings, and a number of barriers exist that bar
access to the few treatments available for Leishmaniasis, including high costs, quality control
issues, low production capacities, and physical geography (Sunyoto, Potet, and Boelaert 2018;
Boer et al. 2011). However, evidence that many people who recover from clinical disease are
generally protected from future reinfection suggests that a vaccine approach is feasible, and there
are currently a large number of potential vaccines being tested in both experimental animal
models and in clinical trials, though none are currently available for human Leishmaniasis (Bush
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et al. 2017; González et al. 2010; López‐Carvajal et al. 2018). Current thinking in the field
+

suggests that a successful vaccine candidate for Leishmaniasis will need to generate CD4 IFN-γ,
as IFN-γ activates macrophages’ microbicidal activity and induces the production of nitric oxide
(NO) and reactive oxygen species (ROS) that can destroy the parasite. Data from clinical trials
that have used heat killed whole Leishmania parasite antigens have resulted in disappointing
outcomes where any observed efficacy is short-lived, and as such, is unlikely to mount protective
immune responses (Khalil et al. 2000; Bahar et al. 1996; Vélez et al. 2005). Live parasites have
also been used in the past to induce immunity with success, however concerns with protracted
and nonhealing lesions as well as parasite passage issues have caused this option to fall out of
favor (Nadim et al. 1983; Khamesipour et al. 2005). A major problem in the field of vaccine
development for Leishmaniasis has been the lack of an identified immunodominant Leishmania
antigen. Recently, however, this deficit has been partially rectified with the discovery of a
Leishmania protein, Leishmania Phosphoenolpyruvate Carboxykinase (PEPCK), which is an
enzyme that is critical for gluconeogenesis. At the peak of Leishmania infection, nearly 20% of all
+

Leishmania-reactive CD4 T cells are PEPCK specific in mice (Mou et al. 2015). Furthermore, the
authors of this study found that peripheral blood mononuclear cells (PBMCs) from people that
have recovered from zoonotic L. major infection recognize PEPCK and express higher IFN-γ and
Granzyme B and increased cell proliferation compared to PBMCs from healthy non-infected
people when stimulated with recombinant PEPCK protein, suggesting the potential of clinical
benefit.
In order to determine if the route of vaccination, intramuscular (IM) or intradermal (ID), would
influence the generation of skin resident T cells, we first tested the ability of a well-defined DNA
vaccine developed for HIV to generate these cells by these two routes. We then created two
synthetic consensus DNA plasmids that encode PEPCK, which represent sequences from six
Leishmania parasites, including L. infantum, L. donovani, L. major, L. mexicana, L. braziliensis,
and L. panamensis. These species represent both Old and New World Leishmania strains that
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can cause cutaneous, mucosal, and visceral leishmaniasis. We immunized mice with these
plasmids either intramuscularly or intradermally by CELLECTRA EP/SEP to evaluate vaccineinduced immunity and assess disease control following challenge. We found that mice immunized
intradermally were better protected against L. major challenge compared to mice immunized
intramuscularly. The levels of protection seen in intradermally immunized mice were similar to
those seen in mice that were previously infected with parasites that exhibit superior control, as
measured by lesion size and parasite burden, and suggest that the intradermal route may be
more efficient at generating Trm cells and protection against Leishmania induced disease
compared to intramuscular vaccination.
Results

Intradermal vs intramuscular HIV Env vaccination at acute and memory time points. An
important outcome for vaccination is to generate long-lived immunity to protect against future
pathogen exposure. Therefore, we sought to examine in pilot experiments the immune responses
elicited post vaccination as well as the response at a memory time point using defined constructs.
C57BL/6 (B6) mice (n=3-5) were immunized with 25 µg of HIV Env DNA vaccine either
intramuscularly with CELLECTRA electroporation (EP), or ID in the abdominal flank with surface
electroporation (SEP), twice, two weeks apart (Figure 24). Spleens and skin at the injection site
were collected ten days post final vaccination to analyze antigen specific responses. A
quantitative ELISpot assay was performed to analyze the IFN-γ response in the spleen, and we
found that mice immunized intramuscularly had an average of 1000 spot forming units (SFU) per
million splenocytes, while intradermally vaccinated mice had an average of 250 SFU. In the skin,
there was no significant difference between IM and ID immunized mice in the frequency of IFN-γ,
+

IL-2, and TNF-α secreting CD4 T cells at the site of immunization, however there was a
+

significant difference in the frequency of IL-2 and TNF-α producing CD4 T cells at the
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contralateral site, suggesting some enhanced honing and mobility of these antigen specific T cells
induced in the skin by ID immunization (Figure 25).

We next examined immune responses 75 days post-final vaccination to study the durability of the
antigen specific responses (Figure 26). There was some contraction of the IFN-γ response, with
an average of 800 SFU/million splenocytes for the IM group and 150 SFU/million for the ID group,
+

but strikingly, there was a significant number of IFN-γ and TNF-α secreting CD4 T cells in the ID
group compared to IM in the skin, suggesting that ID immunization has the potential to generate
long lasting immunity at the site of vaccination in the skin. We did not observe a significant
+

number of antigen specific CD4 T cells at the contralateral site at the memory time point in this
model. Encouraged by these data, we next studied intradermal vaccination in a Leishmania
model for which a mouse challenge exists.

Development of consensus Leishmania PEPCK vaccine. Challenges in Leishmania vaccine
development are due in part to the lack of understanding of the antigens capable of eliciting
+

potent Th1 IFN-γ CD4 T cell responses. However, recent work by Mou et. al has identified a
+

conserved dominant protein, PEPCK, that elicited strong CD4 T cell responses. They found that
+

~17% of Leishmania reactive CD4 T cells were PEPCK specific at peak immune response
during L. major infection. Given this robust response, we designed two constructs that encode
consensus sequences for PEPCK to maximize coverage of both Old and New World strains of
Leishmania (Tables 1 and 2). The PEPCK genes were inserted into a pVax1 backbone under the
control of a CMV immediate-early promoter and IgE leader. Construct expression in vitro was
confirmed using Western blot, to detect binding to PEPCK (Figure 27). Expression of PEPCK was
observed in the lysates of transfected cells, but was not observed in the supernatant.
PEPCK plasmid delivery induces strong cellular IFN-γ responses following intramuscular
vaccination. As IDM2 and PB differ by 7.5% in their amino acid sequences, we wanted to verify
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that both plasmids were immunogenic, and to determine whether there might be an advantage to
delivering both plasmids in a vaccine strategy. We performed intramuscular DNA delivery of
either IDM2 or PB in C57BL/6 mice at a dose of 20 µg each, followed by EP, two times, two
weeks apart. Ten days after final vaccination, we analyzed the degree of immune responses by
isolating splenocytes. A quantitative ELISpot was performed to determine the number of PEPCK
specific IFN-γ secreting T cells responded to vaccination (Figure 28). Both mice vaccinated with
IDM2 or PB mounted a robust immune response, with an average of 2500 SFU/million and 3700
SFU/million splenocytes against IDM2 and PB respectively. Strikingly, there were a much greater
number of T cells that responded to peptides in Pool 1 of PB, compared to the Pool 1 of IDM2,
potentially suggesting additional epitopes that the T cells are recognizing. Based on this
observation, we decided to combine the two plasmids into one vaccine for the reminder of the
studies.
Delivery of both PEPCK plasmids as one vaccine induces strong systemic response
following IM and ID vaccination. Given that the majority of vaccines administered today are
delivered intramuscularly, we wanted to verify that our PEPCK constructs would be immunogenic
whether administered IM or ID. We performed PEPCK (IDM2 and PB) vaccination either IM in
C57BL/6 (B6) mice (n=5) with a dosage of 40 µg total of DNA (20 µg IDM2, 20 µg PB) or ID (n=5)
with the same dosage, followed by IM-EP or ID-SEP, two times, two weeks apart. The ID-SEP
device is less invasive and targets the epidermis. Ten days after final vaccination, we analyzed
the degree of immune responses by isolating splenocytes. A quantitative ELISpot was performed
to determine the number of PEPCK specific IFN-γ secreting T cells responded to vaccination
(Figure 29). Both mice vaccinated IM or ID mounted a robust immune response, with an average
of 1600 and 1800 SFU/million splenocytes against IDM2, and 2500 and 2200 SFU/million
splenocytes against PB, respectively. T cell polyfunctionality has been shown to be protective in
some models, thus we sought to assess the quality of T cells that were responsive to our
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+

vaccination. We found that PEPCK specific CD4 T cells secreted IFN-γ, IL-2, and TNF-α (Figure
29). Furthermore, we observed a humoral response to PEPCK vaccination by IFA. Sera from
PEPCK immunized mice were used to detect antibody binding to IDM2/PB transfected HEK293T
cells. Natural infection with Leishmania induces a robust humoral response, although it is still
unclear the role of antibodies in infection and protection. A large number of studies in mice have
found that IL-4 mediated Th2 response, i.e. antibody skewing, to be detrimental to protection
against Leishmania, however others have found antibodies to play a protective role in challenge
models. These discrepancies may be attributed to the differences in immune responses
generated by different parasite strains, and continue to be teased out. It is apparent however that
+

a predominant Th1 CD4 IFN-γ response is protective in multiple Leishmania strains, and as such
the primary focus and target of these studies.
Intradermal delivery of PEPCK elicits robust IFN-γ responses in the skin. With ~90% of all
Leishmaniasis cases presenting in the skin, potential therapies for the infection should be able to
induce immune responses in this important organ. The vaccine must also be able to induce T
cells that are capable of homing to the point of parasitic infection, even when the vaccination site
is not in close proximity. To address this, we compared the immune responses mounted in the
skin at the site of immunization as well as contralateral sites in response to PEPCK vaccination
given by either the IM or ID route. We found that ID immunization resulted in a high frequency of
+

IFN-γ and TNF-α secreting PEPCK specific CD4 T cells in the skin at the immunization site
(Figure 30). We did not detect any significant vaccine induced immune responses in the skin of
+

mice immunized IM. More importantly, PEPCK specific CD4 T cells were found in the skin
contralateral to the vaccination site, suggesting that this immunization strategy generated T cells
able to home and travel throughout to non-inflamed skin.
Immune responses elicited by PEPCK vaccination are durable. As one of the major issues in
Leishmania vaccine development is the durability of immune responses, we sought to examine
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responses generated at a memory time point. We immunized mice as above and harvested
spleens 45 days post final vaccination. As expected, IFN-γ responses contracted, with an
average 1200 and 500 SFU/million splenocytes against IDM2 in the IM and ID groups, and 2000
and 800 SFU/million splenocytes against PB, respectively (Figure 31). In the spleen, both IM and
ID groups were able to maintain IFN-γ, IL-2, and TNF-α responses, with the IM group maintaining
the highest frequency. Splenic responses appear to be most affected in the ID group with a three
fold contraction in IFN−γ responses measured by ELISpot, compared to the IM group that was
able to maintain similar numbers of antigen specific IFN-γ secreting T cells. However, this was not
true in the skin. Mice that were immunized ID were able to maintain a more significant frequency
+

of IFN-γ producing CD4 T cells in comparison to mice immunized IM (Figure 32).
Intradermal vaccination of PEPCK DNA vaccine leads to better disease control compared
to intramuscular vaccination. To determine the levels of protection against L. major challenge
by each delivery route, naïve, vaccinated and previously challenged control mice were challenged
in the ear. The challenged ear from each group was collected to analyze the parasite burden at
the site of challenge. In response to L. major challenge and inflammation, the ear will form
parasitic lesions, thicken, and become inflamed. Naïve mice were unable to control disease, and
as such exhibited thickened ears, whereas ID immunized and immune mice maintained a much
lower ear thickness, and IM immunized mice had an intermediate presentation (Figure 33). ID
immunized mice were able to lower their parasite burden by nearly three logs, very similar to the
parasite burden seen in immune mice, while IM immunized mice lowered their parasite burden by
two logs. More strikingly, at a memory time point, ID immunization is still able to significantly
reduce parasite burden, while IM immunized mice seem to lose parasite control, suggesting long
lasting protection against challenge. These experiments suggest that ID immunization has the
potential to generate long-lasting control of L. major infection, by a simple and less invasive
immunization approach.
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Discussion
Leishmaniasis is an important neglected tropical disease that can cause severe
disfiguring lesions or fatal visceral infections, and although there have been substantial efforts for
decades to develop a Leishmania vaccine, no options exist yet for this infection. There is
evidence that a primary infection with Leishmania parasite leads to protection against future
reinfection, suggesting the possibility of a vaccine; however there have been reported cases of
people being infected with multiple parasite species, highlighting the need for a vaccine that can
+

provide broad protection across species. As CD4 IFN-γ production is associated with protection
and disease resolution, many candidates have been screened for their ability to elicit this immune
+

response. A recent study found that CD4 T cells that resided in the skin following a primary
infection in mice infected with L. major provided the best protection over disease burden (Glennie
et al. 2015). Thus, after mice had resolved an infection, the authors of the study were able to find
+

Leishmania-specific CD4 T cells present at skin sites distant from the site of the primary lesion.
Furthermore, skin grafting experiments have demonstrated that tissue resident memory T cells
(Trm cells) were maintained in the absence of persistent parasites and could provide significant
protection independent of any systemic immune responses. Taken together with multiple studies
showing the superior protective capacity of tissue resident memory T cells against many other
infections, these results indicate that a candidate Leishmania vaccine should elicit Trm cells.
In these studies we provide insight on the potency and durability of intradermal vaccination using
the SDNA platform in two different models. We observe that ID immunization is able to induce
systemic immune responses post vaccination, as well as maintain immune responses in the skin
at memory time points. We demonstrate that ID delivery of PEPCK DNA is able to protect mice
from disease burden at levels similar to those seen in immune mice, and superior to IM injection,
both soon after vaccination as well as at later time points. ID immunization resulted in reduced
ear thickness post L. major challenge, and a three-log reduction in parasite burden in comparison
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to naïve mice. In contrast, while IM immunization generated a strong systemic cellular response,
the T cell responses in the skin were limited, and protection against parasite burden was not as
robust as that seen following ID immunization. We have previously demonstrated that the most
optimal protection against Leishmania challenge in mice is likely elicited from a combination of
skin resident and circulating effector T cells (Glennie, Volk, and Scott 2017). With this work, we
have shown that while IM and ID PEPCK delivery both induce similar levels of antigen specific
cellular responses systemically, only ID immunized mice are able to significantly drive PEPCK
specific T cells in the skin, resulting in enhanced protection against L. major challenge. These
results indicate the superior ability of ID DNA vaccination in the Leishmania context to induce skin
resident T cells and protective immune responses, and provide practical information needed for
translating this vaccine from a mouse model to human study.
While our studies have identified an appropriate T cell population to target in a vaccine, the other
major hurdle has been identifying appropriate vaccine candidates that generate effective longterm immunity. A substantial step forward was the identification of a Class II restricted
immunodominant antigen (PEPCK) in Leishmania (Mou et al. 2015). At peak infection in mice,
+

over 12% of the CD4 T cells in the blood recognized PEPCK, and vaccination with PEPCK
protein could induce significant protection against a L. major challenge. Moreover, PEPCK is
conserved in many different species of Leishmania, including those that cause both cutaneous
and visceral disease, making it likely that it could be part of a pan-leishmania vaccine. Consensus
vaccines have the potential to induce cross protection across species, making it possible to
envision a single vaccine that could provide broad protection against a number of Leishmania
parasite strains. Therefore, we chose a consensus PEPCK vaccine for our studies of how best to
induce skin resident T cells. While intradermal SEP PEPCK vaccination was able to limit disease
against L. major challenge and reduce parasite burden post vaccination and at a memory time
point, mice that were previously infected with parasites still had lower parasite burden, suggesting
room for improvement. As previously challenged mice are whole parasite experienced, including
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other antigens besides PEPCK may help improve vaccine-induced immune responses and
further reduce parasite burden as well as lesion size and inflammation. As the mice are
challenged with two million parasites, it may also be the case that the immune system “sees”
much more antigen overall in previously challenged mice compared to the amount delivered in
our vaccination studies. Dosing studies that examine the impact of delivering higher doses of
total antigen are warranted. Although the ratio of responses to the different peptide pools remain
the same, the level of cellular responses observed when IDM2 and PB are delivered separately
are higher than when the two are combined, suggesting that there may be some antigen
interference occurring in the one injection site schema. Future studies that investigate whether
delivery of the two plasmids at separate sites can enhance immunogenicity and lead to better
disease control should be explored.
The notion that T cells primed in a specific site are more likely to return to that site as effector
cells is well established, and therefore it is consistent that the ID route may be superior to the IM
route for generating skin resident T cells. An excellent example of this concept comes from the
earliest vaccine, the use of scarification with vaccinia, which not only generates resident memory
T cells at the site of immunization, but also leads to the accumulation of Trm cells in sites distant
from the immunized skin (Jiang et al. 2012). Similarly, our studies demonstrate that ID
immunization also generates global immunity in the skin, in a platform that could easily be
transferred to human vaccination. Aside from a better ability to generate skin resident T cells,
there may be additional advantages to the ID route. As the skin contains more antigen-presenting
cells compared to the muscle, it is believed that ID delivery may result in a more efficient
vaccination, potentially leading to a dose-sparing effect. This could have a significant impact in
the pandemic vaccine field, where there is always a fear of the limited supply of available doses.
Data from rabies and influenza clinical trials suggest that ID delivery can maintain similar antibody
titers while reducing dose, when compared to IM delivery (Resik et al. 2010). Intradermal
vaccination is also considered more tolerable than intramuscular, which can have a positive
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impact on vaccination rates and adherence, and with the continued development of intradermal
devices that reduce the need for needles, reduced needle stick injuries and greater safety may
follow.
As the climate continues to change, Leishmania, endemic to tropical and subtropical regions, will
continue to spread throughout the globe. More therapies are desperately needed to treat
Leishmaniasis patients, and an effective vaccine could dramatically reduce the burden associated
with this disease. Our studies in mice provide a foundation for how best to translate this
experimental vaccine into a practical effective vaccine for human Leishmaniasis, and
demonstrate the superior nature of the ID route for generating skin resident Trm cells.
*Modified from: Louis L, Clark M, Wise MC, Glennie N, Wong A, Broderick K, Uzonna J, Weiner
DB, Scott P. Intradermal synDNA vaccination generates skin-resident T cells and protection
against Leishmania major. Infection and Immunity. 2019; 87(8) 1-14
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Figure 24. Intramuscular and intradermal delivery of Env DNA vaccine induces IFN-γ
responses in the spleen
C57BL/6 mice (n = 3-5 mice/group) received an intramuscular or intradermal DNA injection and
EP/SEP of 25 µg HIV Env vaccine alone two times at two week intervals in the tibialis anterior muscle
or abdominal flank. Spleen and skin were harvested 10 days after the final immunization. ELISpot
analysis of IFN-γ T cell responses against pooled Env peptides shown above.
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Figure 25. Intradermal delivery of Env DNA vaccine induces antigen specific responses in the
skin at immunization and contralateral sites.
C57BL/6 mice (n = 3-5 mice/group) received an intramuscular or intradermal DNA injection and
EP/SEP of 25 µg HIV Env vaccine alone two times at two week intervals in the tibialis anterior muscle
+
or abdominal flank. Skin was harvested 10 days after the final immunization. Antigen specific CD4 T
cell responses measured by intracellular cytokine staining 10 days after final immunization. Error bars
represent standard error of mean. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001
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Figure 26. Intradermal delivery of Env DNA vaccine induces antigen specific responses in the
skin at immunization site at a memory timepoint.
C57BL/6 mice (n = 5 mice/group) received an intramuscular or intradermal DNA injection and EP/SEP
of 25 µg HIV Env vaccine alone two times at two week intervals in the tibialis anterior muscle or
abdominal flank. Spleen and skin was harvested 75 days after the final immunization. ELISpot
+
analysis of IFN-γ responses in the spleen. Antigen specific CD4 T cell responses measured by
intracellular cytokine staining 75 days after final immunization. Error bars represent standard error of
mean. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001
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Parasite

Leishmaniasis manifesta.on

L. infantum

Visceral, cutaneous

L. donovani

Visceral

L. major

Cutaneous

L. mexicana

Cutaneous

L. panamensis

Cutaneous

L. braziliensis

Mucosal

Table 2. Common forms of Leishmaniasis manifestation

Table 1. Common forms of Leishmaniasis presentation
Different strains of Leishmania parasites can drive different Leishmaniasis presentation. Th
Different strains of Leishmania parasites can drive different Leishmaniasis presentation. These
were chosen for the consensus vaccines to cover a broad range of clinical presentations.
strains were chosen for the consensus vaccines to cover a broad range of clinical presentations.
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infantum

donovani

major

IDM2

mexicana

braziliensis

PB

donovani

0.008

major

0.019

0.027

IDM2

0.025

0.025

0.017

mexicana

0.061

0.061

0.051

0.035

braziliensis

0.092

0.090

0.086

0.075

0.098

PB

0.094

0.092

0.086

0.075

0.098

0.006

panamensis

0.084

0.086

0.075

0.065

0.088

0.015

panamensis

0.010

Table 3. Diversity Table of amino acid differences between Leishmania strain PEPCK and
Table 2. Diversity
table of amino acid differences between Leishmania strain PEPCK and consensus
consensus
vaccines

vaccines
The evolutionary history was inferred by the neighbor joining method and all evolutionary distances were
The
evolutionary history was inferred by the neighbor joining method and all evolutionary
computed using the Poisson correction method and are in the units of amino acid substitutions per site. All
distances
were
using
the Poisson
correction method and are in the units of amino acid
positions with
lesscomputed
than 30% site
coverage
were eliminated.

substitutions per site. All positions with less than 30% site coverage were eliminated.

85

infantum

donovani

major

consensusIDM2

mexicana

panamensis

braziliensis

consensusPB

0.010

empty

PB

IDM2

75
50
Actin

37
BamHI

IDM2

XhoI

BamHI

PB

BGH pA
PCMV

XhoI

BGH pA
PCMV

pVax

pVax
Kanamycin

Kanamycin

IDM2 sequence
MDWTWILFLVAAATRVHSAPIIHRNLTAPELVQWALKLEKDTKLSARGALCVLSYAKTGRSPRDKRVVDTDDVRENVDWGSVNVKLSEESFA
KVKKRAMDFLNSRDHLFIVDCFAGHDERYRLKVRVITARPYHALFMYNMLIRPTQQELENFGEPEYTIYNAGEHSADPSVPGVTSTTSVSLNF
KTGEEVILGTEYAGEMKKGILTVMFELMPRQGHLCMHASANVGKKGDVTVFFGLSGTGKTTLSADPNRMLIGDDEHVWTDRGVFNIEGGCY
AKAIGLNPKTEEEIYNAVRFGAVAENCTLDKATHEIDFNDESICKNTRVAYPLEHIPGALTHAVAGHPNNVIFLTNDAFGVMPPVARLTPEQAMF
WFIMGYTANVPGVEAGSTPVAKPIFSSCFAGPFLVRHATFYGEQLAKKMTEHNARVWLLNTGYAGGRADRGAKRMPLKVTRAVIDAIHDGSL
DKEEYCVYPGWGLQIPKRCARVPAQLLDPRKAWKDVKAFNETTKELVAMFQASFQKRFAAKASEALKSAVPKYVETAHL

Figure 27. Optimized PEPCK constructs express in vitro

Diversity among Leishmania parasite and consensus sequences. The evolutionary history was
inferred
by the neighbor joining method and all evollutionary distances were computed using the
PB sequence
Poisson
correction method and are in the units of amino acid substitutions per site. All positions with
MDWTWILFLVAAATRVHSAPIIHRNLTVPELVQWALKLEKDTVLSARGTLCVLSYAKTGRSPRDKRVVDTDDVRSNVDWGSVNMKLSEESF
AKAKKHAIDFLNSREHMFVVDCFAGHDERYRLKVRVITARPYHALFMYNMLIRPTQKELESFGEPEYTIYNAGECSADPSVPGITSKTSVSLN
less
than 30% site coverage were eliminated. Map of plasmid construct design for consensus
FKTQEEVILGTEYAGEMKKGILTVMFELMPRQGHLCMHASANVGKKGDVTVFFGLSGTGKTTLSADPNRMLIGDDEHVWTDRGVFNIEGG
sequences.
Each plasmid contains a CMV promoter followed by an IgE leader sequence beside the
CYAKAIGLNPKTEEEIYNAVRFGAVAENCRLDKTTHEIDFNDESICKNTRVAYPLEHIPGALTHAVAGHPRNVIFLTNDAFGVMPPVARLTPEQA
MFWFIMGYTANVPGVEAGNLPVAKPVFSACFAGPFLVRHATFYGEQLAKKMTEHNARVWLLNTGYAGGRADRGAKRMPLKVTRAVIDAIH
consensus
PEPCK sequence. HEK293T cells were transfected with either IDM2 or PB consensus
DGSLDREEYIVYPGWGLHIPKKCARVPSHLLDPRKAWKDVKAFNHTAKELVMMFQESFEKRFASKASDALKSAVPKYVECAHL
plasmids that contained a C-terminal HA tag for detection. Lysates from these cells were used in
Western blot for detection of plasmid expression under reducing conditions.
Figure 13. Plasmid map and sequences of PEPCK plasmids, IDM2 and PB
Plasmid map of IDM2 and PB constructs. IDM2, consensus sequence of PEPCK from parasite strains infantum, donovani,
major, and mexicana. PB, consensus sequence of PEPCK from parasite strains panamensis and braziliensis. Both
plasmids are under the immediate-early CMV promoter. Amino acid sequences of both constructs are provided below.
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Figure 28. IDM2 and PB consensus PEPCK vaccines are immunogenic and induce IFN-γ
responses in the spleen
C57BL/6 mice ( n = 5 mice/group) received an intramuscular DNA injection and EP of either 20 µg of
IDM2 vaccine (consensus of PEPCK from L. infantum, donovani, major, and mexicana) or 20 µg of
PB vaccine (consensus of PEPCK from L. panamensis and braziliensis) two times at two week
intervals in the tibialis anterior muscle. ELISpot analysis of IFN-γ responses 10 days after final
immunization.
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Figure 29. Intramuscular and intradermal PEPCK immunization induces systemic antigen
specific responses
C57/BL6 mice (n = 4-5 mice/group) were immunized twice two weeks apart either intramuscularly or
intradermally. Spleens and sera were harvested 10 days post final vaccination to analyze antigen
specific T cell responses. The frequency of PEPCK specific IFN-γ responses after vaccination was
+
determined by ELISpot assay in response to pooled PEPCK peptides. PEPCK specific CD4 T cell
responses to each consensus plasmid by intracellular cytokine staining after peptide stimulation.
HEK293T cells were transfected with PEPCK plasmids and sera from mice immunized with the
constructs was used to detect antibody binding to PEPCK by IFA.
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Figure 30. Intradermal PEPCK vaccination induces antigen specific CD4+ T cells at
immunization and contralateral sites in the skin
C57/BL6 mice (n = 4-5 mice/group) were immunized twice at a two week interval either IM or ID EP.
Flank or tibialis anterior (TA) skin from vaccination and contralateral site was harvested 10 days post
+
final vaccination and analyzed for PEPCK specific CD4 T cell responses by intracellular staining post
PEPCK peptide stimulation.
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Figure 31. PEPCK specific IFN-γ responses are maintained in the spleen at a memory
timepoint
C57/BL6 mice (n = 4-5 mice/group) were immunized twice two weeks apart either intramuscularly or
intradermally. Spleens were harvested 45 days post final vaccination to analyze antigen specific IFN-γ
T cell responses in memory phase. The frequency of PEPCK specific IFN-γ responses induced after
vaccination was determined by ELISpot assay in response to pooled PEPCK peptides. PEPCK
+
specific CD4 T cell responses to each consensus plasmid by intracellular cytokine staining after
peptide stimulation are shown above. Error bars represent standard error of mean. * p < 0.05, ** p <
0.005, *** p < 0.0005, **** p < 0.0001
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Figure 32. PEPCK specific IFN-γ responses are maintained in the skin at a memory timepoint
C57/BL6 mice (n = 4-5 mice/group) were immunized twice two weeks apart either intramuscularly or
intradermally. Skin at the immunization site was harvested 45 days post final vaccination to analyze
+
antigen specific IFN-γ T cell responses in memory phase. PEPCK specific CD4 T cell responses to
each consensus plasmid by intracellular cytokine staining after peptide stimulation are shown above.
Error bars represent standard error of mean. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001
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Figure 33. Intradermal PEPCK vaccination protects mice against L. major challenge
C57/BL6 mice (n =5 mice/group) were immunized once intradermally or intramuscularly with PEPCK
and challenged with 2 million L. major parasites either 10 days or 45 days post immunization. Ear
thickness curve plotting ear thickness over the span of challenge. The parasite burden in the
challenged ear was quantified on day 55 post final immunization or day 90 following final
immunization. Error bars represent standard error of mean. * p < 0.05, ** p < 0.005, *** p < 0.0005,
**** p < 0.0001
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CHAPTER 5 – Discussion and Future Directions

The potential of the DNA platform to revolutionize the way that vaccines are made and delivered
has not been fully realized today as early setbacks in scaling DNA from small preclinical animal
models to large animals and humans relegated DNA to a background role as boost
immunizations to viral vector primes in vaccine schemes. However, advancements in the
technology, including electroporation, concentrated DNA formulations, and sequence optimization
have significantly improved the outcomes of DNA vaccination to levels seen in viral vector
vaccine delivery. DNA vaccines maintain a stellar safety profile, as they are nonlive and
nonreplicating, eliminating the risk of attenuation reversion in high-risk populations that may be
immunocompromised. Over 30,000 people have been vaccinated with DNA with no serious
adverse effects, alleviating worries of DNA integration that has long concerned the field. DNA
vectors are not immunogenic, allowing for repeated administration without immune interference or
concerns about previous viral exposure. Additionally, DNA is very stable, limiting the need for a
cold chain, which in turn makes it an ideal candidate for delivery in resource strained settings.
As the quest for novel adjuvants that enhance vaccine induced responses and skew the response
in the direction that favors protection continue, investigation of novel cytokines that can elicit
these responses will grow. In this thesis, I’ve highlighted the potential of the truncated IL-36 family
(subject of chapter 3) to boost immune responses following intramuscular delivery of three
separate SDNA vaccines, and show that truncated IL-36 gamma can enhance protection of a non
protective dose of Zika SDNA vaccine against a lethal Zika challenge. We first demonstrate that
truncation of IL-36 beta results in enhanced immune responses against a HIV DNA vaccine. We
+

+

then show that truncated IL-36 beta and IL-36 gamma exert their influences on CD4 and CD8 T
cells respectively to enhance cellular responses. In an influenza DNA vaccine model, truncated
IL-36 gamma was able to increase antibody binding titers, while maintaining the avidity of the
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antibodies, whereas codelivery of truncated IL-36 alpha and IL-36 beta were detrimental to
antibody avidity. Lastly, we show that a non-protective dose alone of a Zika DNA vaccine does
not generate significant cellular responses, nor protect mice against a Zika challenge. The
combination of Zika vaccine with truncated IL-36 gamma was able to synergize to mount a robust
cellular response that was able to protect mice against challenge.
Future IL-36 applications
As the IL-36 cytokine family is primarily expressed in the skin, it is highly conceivable that
infections and diseases that originate in the skin may be great targets to further study IL-36
biology and investigate adjuvant activity. Merkel cell carcinoma, driven in part by the Merkel cell
polyomavirus in most cases, is a relatively rare form of cancer that tends to occur on the face,
head, and/or neck. While the virus that causes this cancer is very common, it is not completely
understood how or why it can drive tumorigenesis in certain adults although increased sunlight
exposure and older age are known risk factors (Becker et al. 2017). The cancer arises in Merkel
+

cells, which are found in the epidermis of the skin. Given the importance of CD8 T cells in
controlling tumor burden, a potential prophylactic or therapeutic vaccine for this cancer would
likely need to elicit this T cell response. The data generated in my thesis project suggests that
+

opt-36γt can elicit vaccine specific CD8 T cell response, and as such may play a role in future
vaccine design studies in this model. The melanoma data from Wang et al showing that tumor
burden is reduced when cancer cells expressing IL-36 gamma are transplanted lends further
credence to the idea that IL-36 may impact cancer intervention responses.
The IL-36 family members have been described as potential immune sentinels that alert the
immune system of danger. Such a role could be beneficial in vaccines where inclusion of an
adjuvant such as IL-36 gamma could potentially jumpstart the immune response and drive either
accelerated vaccine induced immunity or magnify overall response. Preliminary data that I’ve
generated in a TERT (nonviral cancer antigen) SDNA vaccine model suggests that opt-36βt can
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boost IFN-γ cellular responses compared to vaccine alone (Figure 34). Inclusion of this adjuvant
and the other IL-36 members in a tumor challenge study in the context of SDNA would give
exciting information to inform whether these cytokines can impact cancer outcome. A follow up to
the Wang melanoma study (X. Wang et al. 2015a) where IL-36 gamma is administered as an
adjuvant to a vaccine targeting melanoma antigens could tease out the ability of the cytokine to
either prevent “tumor take,” slow down tumor growth, promote enhanced TILs, or even drive
tumor clearance.
We observed enhanced antibody avidity in our influenza studies in mice adjuvanted with opt-36γt,
suggesting a maturation of the antibodies induced. This leads to the question if mice immunized
with opt-36γt experience greater somatic hypermutations in their antibodies, and if so, whether
this is due to enhanced T follicular helper responses. Studies to examine the impact of IL-36
gamma on T follicular helper and B cells in the germinal center would help shed further light on
the roles of IL-36 in enhancing immune responses during vaccination and under normal
physiologic conditions.
Aberrant overexpression of IL-36 cytokines has been implicated in disorders of the skin, however
we have seen great promise of opt-36γt and opt-36βt to enhance vaccine induced immune
responses. Studies to examine whether IL-36 plasmid codelivery in the skin would mediate
toxicity are very important. As many infections are mediated in the skin, adjuvant delivery in the
skin could potentially further boost protection by recruiting CTLs and enhancing antibody
production in the skin where the breach may occur.
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Future directions: gene encoded adjuvants
As the number of infectious diseases and rates of certain cancers increase, the need for novel
adjuvants that increase vaccine induced immune response, provide dose sparing benefits, and
broaden immune response breadth in traditionally immunocompromised patients, will increase.
The success of ASO1 as an adjuvant to the herpes zoster vaccine helps demonstrates some of
the potential that adjuvants have to offer. Gene encoded adjuvants stand to offer even greater
benefit as transfected cells with both vaccine target and adjuvant can sway the immune response
at the same time, potentially leading to greater immune responses. Investigations of ligands that
target TLRs appear particularly promising as adjuvants. Recent studies have shown that flagellin,
a TLR5 agonist, can act as a gene adjuvant in a vaccine against Toxoplasma gondii, and
enhance humoral and cellular responses (Maraghi et al. 2019). Yet another study investigated
flagellin’s ability to enhance vaccine responses as an adjuvant scaffold and observed augmented
responses to an HIV epitope (Ajamian et al. 2018). Studies that investigate the use of novel
cytokines to further current understanding of their roles in immunity as well as biological roles in
homeostasis will continue to advance the field.
While more studies, both in appropriate preclinical models and clinical trials, are beginning to
highlight the efficacy of SDNA vaccines in a number of infectious diseases and cancer, there is
still much more work to be done to further refine the technology. When I first began my thesis
work, there were relatively few studies that examined the immune response generated post
SDNA vaccination in the skin. Of the studies that did investigate SDNA vaccination in the skin,
primarily humoral responses were observed and reported. The lack of information regarding the
cellular responses elicited by DNA vaccination in the skin led me to investigate the immune
response generated post intradermal delivery of two DNA vaccines. Using an established HIV
Env and a novel Leishmania PEPCK vaccine (the subject of chapter 4), we outline the
development of an effective intradermal vaccine strategy that generates durable antigen specific
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T cells in the skin, and enhances disease control in a Leishmania infection model. During my
thesis work, results from a number of clinical studies were released that further reinforced the
advantages of intradermal vaccine delivery (Figure A1).
Infection with Zika virus is generally a self-limiting infection characterized by fever, arthritis, and
rash. However, there have been many reported cases of Zika virus induced Guillian-Barre
Syndrome as well as congenital birth defects during pregnancy. There are currently no approved
vaccines or therapeutics for this infection, and so a lot of work has been done to rectify the
situation. A clinical study that examined immune responses to an intradermal vaccine delivery of
a Zika SDNA vaccine in healthy volunteers found that 100% of the participants developed binding
antibodies against the vaccine, and 62% of them developed neutralizing antibodies following
vaccination. These antibodies were able to protect IFNAR -/- mice against Zika challenge.
The 2014 Ebola outbreak quickly spurned multiple groups and agencies to develop vaccine
candidates and monoclonal antibody (mAb) therapies that could induce protective immune
responses against the virus. There has been great encouraging data suggesting that these
interventions, both on the vaccine and mAb arm, are effective, however most of the vaccine
studies have assessed immune responses generated post intramuscular immunization. A clinical
study published earlier this year assessed the immune responses generated after intramuscular
and intradermal vaccination of an Ebola glycoprotein SDNA vaccine. The authors found that while
intramuscular and intradermal vaccination both induced antibody responses, the volunteers in the
ID cohort had the fastest and steepest rise in antibody production compared to IM. This rapid
increase in antibodies will likely prove critical in the context of active outbreak.
The study presented in this thesis is the first to show that intradermal delivery of Leishmania
+

PEPCK can induce PEPCK specific CD4 T cells in the skin. After two immunizations of two
separate consensus DNA plasmids in the muscle, we observed the induction of robust systemic
cellular responses that highlighted immunogenic epitopes in areas of the protein not previously
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described. Recognizing the need for a simpler vaccine strategy, we combined the two plasmids
into one injection, and observed the maintenance of cellular responses to respective peptide
pools. Importantly, although intradermal and intramuscular PEPCK vaccination generated similar
responses systemically, only mice immunized in the skin were able to elicit these responses in
the skin, which is critical for infections that originate in the skin. We also determined that the
responses generated by intradermal delivery are durable and are maintained in the skin at a
memory time point, which is crucial in the Leishmania field given the number of candidates that
show initial protection that wanes over time. Following a Leishmania parasite challenge, mice that
were immunized intradermally maintained better disease control compared to those immunized
intramuscularly. ID immunized mice showed decreased ear thickness as well as parasite burden
compared to IM mice. This control that we observed was not quite as strong as mice that were
previously infected with parasites (gold standard), suggesting there is room for improvement in
our vaccine strategy.
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Figure 34. Opt36βt boosts IFN-γ T cell responses compared to vaccine alone against
cancer antigen
C57BL/6 mice (n= 5 mice/group) were immunized three times, at two week intervals with either
25 µg of mTert vaccine alone, or 25 µg of mTert and 11 µg of opt36βt. Spleens were harvested 8
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C57Bl/6 mice (n = 5 mice/group) were immunized three times at two week intervals with either 25
µg of mTert vaccine alone, or 25 µg mTert and 11 µg of opt-36βt. Spleens were harvested 8 days
after final immunization. ELISpot analysis of IFN-γ T cell responses depicted above.
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Future directions: intradermal delivery
To date, the only human disease that has been globally eradicated is smallpox. Of note, this is
one of the few vaccines, besides Bacille Calmette-Guerin (BCG) and rabies, currently
administered intradermally. Work by Liu et al. (Liu et al. 2010) has shown that a major part of the
success of this vaccine is due to skin delivery, not just the immunogenicity of the vaccine. As the
skin is such an accessible tissue for vaccination, it would be reasonable to measure a vaccine’s
efficacy post intradermal delivery as well as the standard intramuscular delivery. The work
highlighted in this thesis as well as clinical data generated in intradermal Zika and Ebola SDNA
vaccine models especially highlight advantages in protective immune responses in the skin for
infections transmitted through the skin by mosquitos and sandflies.

Future directions: PEPCK delivery
Given that we observed higher systemic responses with single immunization of IDM2 or PB at a
20 µg dose than we did when we administered both together in one vaccine at a 40 µg dose, we
suspect that some antigenic interference is occurring. While it would be simpler and more
clinically relevant to maintain the combination vaccination, future studies should be done to learn
whether the immune responses elicited would be higher if the two plasmids were given at
separate sites and if this affects the responses seen in the skin and lead to better parasite
control.
While it has been difficult to estimate the number of Leishmania parasites transmitted during a
sandfly bite, the best estimates put this number in the range of about 1000 parasites when
sandfly transmission to mice is studied, which is much lower than the 2 million L. major parasites
we delivered in our studies (M. E. Rogers et al. 2004). While there will be variability in people
when infected with Leishmania parasites, revisiting our studies with a lower initial infectious dose
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of parasite may better recapitulate what may happen in natural settings, and may allow us a
better understanding of how efficacious the intradermal delivery of PEPCK can be.
All of the studies for intradermal DNA delivery illustrated in this thesis have been done in the
C57Bl/6 mouse strain, as they represent the classic model to study L. major infection. C57BL/6
mice are known to generate immune responses that skew towards a Th1 response, which is
needed for parasite and disease control. Th2 responses have long been associated with
exacerbated disease, though a few reports show either no impact of Th2 antibody responses
(Shahi et al. 2013; K. A. Rogers et al. 2002), or some protection. Balb/C mice, which are known
to skew towards a Th2 response, generally develop severe ulcerating lesions and progress
towards death following Leishmania challenge. Investigating whether PEPCK intradermal delivery
in the skin can protect these mice from death and severe disease in spite of their genetic
background would further support the case for the efficacy of vaccine delivery in the skin in the
context of Leishmania.

Summary and concluding thoughts
In summary, we described through multiple studies the importance of the skin as a provider of
cytokines that may be used to enhance vaccine responses as well as a privileged site that may
offer a greater payoff in vaccine strategies. We show that intradermal delivery of PEPCK offers
better disease control and parasite burden compared to intramuscular delivery after Leishmania
challenge. We also show that truncated IL-36 gamma is able to enhance cellular responses post
vaccination in three separate models and that it can provide significant protection against Zika
challenge. Future studies should focus on developing and optimizing intradermal strategies
across a number of infectious disease targets and cancer, as well as discovering novel molecules
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that can serve as adjuvants to boost responses to vaccines that may not be immunogenic enough
on their own.
The potential of the new synthetic DNA vaccine platform to radically improve global health cannot
be understated. With the improvements in the platform, DNA represents an opportunity to rapidly
respond to pandemics, expand therapies in resource strained settings that have few options, as
well as provide clinical benefit to underserved populations that may have little recourse for
treatment. From an economic standpoint, DNA vaccines require no viral or protein purification, no
massive warehouses and tanks to generate product, allowing for greater manufacturing and
accessibility to a wider audience. As more clinical studies are done to evaluate the efficacy of
intradermal DNA delivery as well as the impact of localized delivery of gene adjuvants, skin
delivery may play an important role in the development of this next generation of DNA vaccines
(Figure A2).
The synthetic DNA platform has enjoyed a major boost in human potency due to a number of
advancements, including electroporation, new DNA formulations, as well as genetic sequence
optimization. The next generation of SDNA vaccines for remaining disease targets will likely also
require multiple efforts to generate vaccine-induced protection. Preliminary data that I’ve
generated suggests that codelivery of opt36βt, with IDM2 vaccine in an intramuscular vaccination
site can enhance IFN-γ T cell responses (Figure 35). Opt36βt is particularly attractive as an
+

adjuvant for PEPCK as it can enhance IFN-γ CD4 T cells, which is critical for protection in this
model. Further studies looking at this vaccine formulation in an intradermal vaccination scheme
will be critical to understanding whether there may be enhanced protection against Leishmania
parasite challenge.
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Figure 35. Codelivery of opt36βt with IDM2 enhances IFN-γ T cell responses in the spleen
C57BL/6 mice (n= 5 mice/group) were immunized two times, at two week intervals with either 20
µg of IDM2 vaccine alone, or 25 µg of IDM2 and 11 µg of opt36βt. Spleens were harvested 10
days after final immunization. ELISpot analysis of IFN-γ T cell responses depicted above.
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CHAPTER 6- Appendix
Intradermal Vaccina.on Trials between 2014- 2019
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Figure A 1. Breakdown of intradermal vaccination clinical targets between Jan. 1, 2014 and
Oct. 31, 2019
Clinical trials launched within the past five years are testing intradermal vaccination against a
wide range of disease targets and conditions
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CHAPTER 7- Publications

The following papers have been published in support of this dissertation, starting with the most
recently published work.
Intradermal synDNA vaccination generates Leishmania specific T cells in the skin and
protection against Leishmania major.
Lumena Louis, Megan Clark, Megan C Wise, Nelson Glennie, Andrea Wong, Kate
Broderick, Jude Uzonna, David B Weiner, Phillip Scott
Abstract
Vaccination remains one of the greatest medical breakthroughs in human history, and has
resulted in near eradication of many former lethal diseases in many countries including the
complete eradication of smallpox. However, there remain a number of diseases for which there
are no or only partially effective vaccines. There are numerous hurdles in vaccine development,
of which knowing the appropriate immune response to target is one of them. Recently, tissue
resident T cells have been shown to mediate high levels of protection for several infections,
although the best ways to induce these cells is still unclear. Here we compare the ability to
generate skin resident T cells in sites distant from the immunization site following intramuscular
and intradermal injection using optimized synthetic DNA vaccines. We found that mice immunized
intradermally with a synthetic consensus DNA HIV Envelope vaccine by electroporation (EP) are
better able to maintain durable antigen specific cellular responses in the skin compared to mice
immunized by the intramuscular route. We extended these studies by delivering a synDNA
vaccine encoding Leishmania Glycosomal Phosphoenolpyruvate Carboxykinase (PEPCK) by EP,
and again found that the intradermal route was superior to the intramuscular route for generating
skin resident PEPCK specific T cells. When challenged with Leishmania major (L. major)
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parasites, we observed that mice immunized intradermally exhibited significant protection, while
mice immunized intramuscularly did not. The protection seen in intradermally vaccinated mice
supports the viability of this platform to not only generate skin resident T cells, but also to promote
durable protective immune responses at relevant tissues sites.

Designed DNA-Encoded IL-36 Gamma Acts as a Potent Molecular Adjuvant Enhancing
Zika Synthetic DNA Vaccine Induced Immunity and Protection In a Lethal Challenge Model
Lumena Louis, Megan C. Wise, Hyeree Choi, Daniel O. Villarreal, Kar Muthumani, David B.
Weiner
Abstract
Identification of novel molecular adjuvants which can boost and enhance vaccine-mediated
immunity and provide dose sparing potential against complex infectious diseases and for
immunotherapy of cancer is likely to play a critical role in the next generation of vaccines. Given
the number of challenging targets for which no or only partial vaccine options exist, adjuvants that
can address some of these concerns are in high demand. Here, we report that a designed
truncated IL-36 gamma encoded plasmid can act as a potent adjuvant for several DNA encoded
vaccine targets including HIV, influenza, and Zika in immunization models. We further show that
the truncated IL-36 gamma (opt-36gt) plasmid provides improved dose sparing as it boosts
immunity to a suboptimal dose of a Zika DNA vaccine resulting in potent protection against a
lethal Zika challenge.
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Rapid Synthetic DNA vaccine development for emerging infectious disease outbreaks
Lumena Louis and David B. Weiner
Abstract
Vaccines are considered among the top feats of modern medicine, saving millions of lives by
inducing immunity to a number of infectious pathogens. As the next generation of vaccines seeks
to address ever more complicated targets including cancer, innovative technologies like synthetic
DNA vaccination that circumvent some of the issues associated with traditional vaccines will likely
prove critical. In addition, compounding factors that may influence immune outcome such as the
microbiome must also be studied in greater detail. Recent clinical studies have suggested that the
presence of certain bacteria in the gut was associated with favorable outcomes in patients
receiving immunogenic chemotherapy. Other studies have also shown that a dysbiosis or
overrepresentation of other bacteria strains was negatively associated with favorable outcome.
Further work needs to be done to more fully understand the influence that the microbiome exerts
on the immune system and vice versa, and the significance of this relationship in designing future
therapies.

108

BIBLIOGRAPHY

Abdallah, Florence, Lily Mijouin, and Chantal Pichon. 2017. “Skin Immune Landscape: Inside and
Outside the Organism.” Mediators of Inflammation 2017. https://doi.org/10.1155/2017/5095293.
Ajamian, Lara, Luca Melnychuk, Patrick Jean-Pierre, and Gerasimos J. Zaharatos. 2018. “DNA
Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 Gp41
Membrane Proximal External Region Immunogenicity.” Viruses 10 (3).
https://doi.org/10.3390/v10030100.
Bahar, Kamal, Yahya Dowlati, Babak Shidani, Mohammad Hossein Alimohammadian, Ali
Khamesipour, Siemin Ehsasi, Reza Hashemi-Fesharki, Saeed Ale-Agha, and Farrokh Modabber.
1996. “Comparative Safety and Immunogenicity Trial of Two Killed Leishmania Major Vaccines
with or without BCG in Human Volunteers.” Clinics in Dermatology, Cutaneous Leishmaniasis, 14
(5): 489–95. https://doi.org/10.1016/0738-081X(96)00071-5.
Becker, Jürgen C., Andreas Stang, James A. DeCaprio, Lorenzo Cerroni, Celeste Lebbé, Michael
Veness, and Paul Nghiem. 2017. “Merkel Cell Carcinoma.” Nature Reviews. Disease Primers 3
(October): 17077. https://doi.org/10.1038/nrdp.2017.77.
Belongia, Edward A., and Allison L. Naleway. 2003. “Smallpox Vaccine: The Good, the Bad, and
the Ugly.” Clinical Medicine and Research 1 (2): 87–92.
Bhardwaj, Nina, Sacha Gnjatic, and Nikhil B. Sawhney. 2010. “TLR AGONISTS: Are They Good
Adjuvants?” Cancer Journal (Sudbury, Mass.) 16 (4): 382–91.
https://doi.org/10.1097/PPO.0b013e3181eaca65.

109

Bharucha, Tehmina, Damien Ming, and Judith Breuer. 2017. “A Critical Appraisal of ‘Shingrix’, a
Novel Herpes Zoster Subunit Vaccine (HZ/Su or GSK1437173A) for Varicella Zoster Virus.”
Human Vaccines & Immunotherapeutics 13 (8): 1789–97.
https://doi.org/10.1080/21645515.2017.1317410.
Boer, M. den, D. Argaw, J. Jannin, and J. Alvar. 2011. “Leishmaniasis Impact and Treatment
Access.” Clinical Microbiology and Infection 17 (10): 1471–77. https://doi.org/10.1111/j.14690691.2011.03635.x.
Boylston, Arthur. 2012. “The Origins of Inoculation.” Journal of the Royal Society of Medicine 105
(7): 309–13. https://doi.org/10.1258/jrsm.2012.12k044.
Bush, Jacob T., Monique Wasunna, Fabiana Alves, Jorge Alvar, Piero L. Olliaro, Michael Otieno,
Carol Hopkins Sibley, Nathalie Strub Wourgaft, and Philippe J. Guerin. 2017. “Systematic Review
of Clinical Trials Assessing the Therapeutic Efficacy of Visceral Leishmaniasis Treatments: A
First Step to Assess the Feasibility of Establishing an Individual Patient Data Sharing Platform.”
PLoS Neglected Tropical Diseases 11 (9). https://doi.org/10.1371/journal.pntd.0005781.
Carbone, Francis R. 2015. “Tissue-Resident Memory T Cells and Fixed Immune Surveillance in
Nonlymphoid Organs.” The Journal of Immunology 195 (1): 17–22.
https://doi.org/10.4049/jimmunol.1500515.
Catalan-Dibene, Jovani, Laura L. McIntyre, and Albert Zlotnik. 2018. “Interleukin 30 to Interleukin
40.” Journal of Interferon & Cytokine Research 38 (10): 423–39.
https://doi.org/10.1089/jir.2018.0089.
Cha, Edward, and Adil Daud. 2012. “Plasmid IL-12 Electroporation in Melanoma.” Human
Vaccines & Immunotherapeutics 8 (11): 1734–38. https://doi.org/10.4161/hv.22573.

110

Chong, Siew-Yen, Michael A. Egan, Michele A. Kutzler, Shakuntala Megati, Amjed Masood, Vidia
Roopchard, Dorys Garcia-Hand, et al. 2007. “Comparative Ability of Plasmid IL-12 and IL-15 to
Enhance Cellular and Humoral Immune Responses Elicited by a SIVgag Plasmid DNA Vaccine
and Alter Disease Progression Following SHIV89.6P Challenge in Rhesus Macaques.” Vaccine
25 (26): 4967–82. https://doi.org/10.1016/j.vaccine.2006.11.070.
Clark, Rachael A. 2015. “Resident Memory T Cells in Human Health and Disease.” Science
Translational Medicine 7 (269): 269rv1. https://doi.org/10.1126/scitranslmed.3010641.
Clavel, Gaëlle, Allan Thiolat, and Marie-Christophe Boissier. 2013. “Interleukin Newcomers
Creating New Numbers in Rheumatology: IL-34 to IL-38.” Joint Bone Spine 80 (5): 449–53.
https://doi.org/10.1016/j.jbspin.2013.04.014.
Clayton, Kalum, Andres F. Vallejo, James Davies, Sofia Sirvent, and Marta E. Polak. 2017.
“Langerhans Cells—Programmed by the Epidermis.” Frontiers in Immunology 8.
https://doi.org/10.3389/fimmu.2017.01676.
Coffman, Robert L., Alan Sher, and Robert A. Seder. 2010. “Vaccine Adjuvants: Putting Innate
Immunity to Work.” Immunity 33 (4): 492–503. https://doi.org/10.1016/j.immuni.2010.10.002.
Deckers, Julie, Hamida Hammad, and Esther Hoste. 2018. “Langerhans Cells: Sensing the
Environment in Health and Disease.” Frontiers in Immunology 9 (February).
https://doi.org/10.3389/fimmu.2018.00093.
Deriu, Elisa, Gayle M. Boxx, Xuesong He, Calvin Pan, Sammy David Benavidez, Lujia Cen, Nora
Rozengurt, Wenyuan Shi, and Genhong Cheng. 2016. “Influenza Virus Affects Intestinal
Microbiota and Secondary Salmonella Infection in the Gut through Type I Interferons.” PLoS
Pathogens 12 (5): e1005572. https://doi.org/10.1371/journal.ppat.1005572.

111

Dietrich, Damien, Praxedis Martin, Vincent Flacher, Yu Sun, David Jarrossay, Nicolo Brembilla,
Christopher Mueller, et al. 2016. “Interleukin-36 Potently Stimulates Human M2 Macrophages,
Langerhans Cells and Keratinocytes to Produce pro-Inflammatory Cytokines.” Cytokine 84
(August): 88–98. https://doi.org/10.1016/j.cyto.2016.05.012.
Dinarello, Charles A. 2013. “Overview of the Interleukin-1 Family of Ligands and Receptors.”
Seminars in Immunology, The IL-1 Family of Ligands and Receptors and the Diversity of Innate
Responses, 25 (6): 389–93. https://doi.org/10.1016/j.smim.2013.10.001.
Ding, Liping, Xiaohui Wang, Xiaoping Hong, Liwei Lu, and Dongzhou Liu. 2017. “IL-36 Cytokines
in Autoimmunity and Inflammatory Disease.” Oncotarget 9 (2): 2895–2901.
https://doi.org/10.18632/oncotarget.22814.
Eckert, R. L. 1989. “Structure, Function, and Differentiation of the Keratinocyte.” Physiological
Reviews 69 (4): 1316–46. https://doi.org/10.1152/physrev.1989.69.4.1316.
Ferraro, Bernadette, Matthew P. Morrow, Natalie A. Hutnick, Thomas H. Shin, Colleen E. Lucke,
and David B. Weiner. 2011. “Clinical Applications of DNA Vaccines: Current Progress.” Clinical
Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 53 (3):
296–302. https://doi.org/10.1093/cid/cir334.
Foster, Alexander M., Jaymie Baliwag, Cynthia S. Chen, Andrew M. Guzman, Stefan W. Stoll,
Johann E. Gudjonsson, Nicole L. Ward, and Andrew Johnston. 2014. “IL-36 Promotes Myeloid
Cell Infiltration, Activation and Inflammatory Activity in Skin.” Journal of Immunology (Baltimore,
Md. : 1950) 192 (12): 6053–61. https://doi.org/10.4049/jimmunol.1301481.
Fynan, E F, R G Webster, D H Fuller, J R Haynes, J C Santoro, and H L Robinson. 1993. “DNA
Vaccines: Protective Immunizations by Parenteral, Mucosal, and Gene-Gun Inoculations.”
Proceedings of the National Academy of Sciences of the United States of America 90 (24):
11478–82.
112

Gaide, Olivier, Ryan O. Emerson, Xiaodong Jiang, Nicholas Gulati, Suzanne Nizza, Cindy
Desmarais, Harlan Robins, James G. Krueger, Rachael A. Clark, and Thomas S. Kupper. 2015.
“Common Clonal Origin of Central and Resident Memory T Cells Following Skin Immunization.”
Nature Medicine 21 (6): 647–53. https://doi.org/10.1038/nm.3860.
Garçon, Nathalie, David W. Vaughn, and Arnaud M. Didierlaurent. 2012. “Development and
Evaluation of AS03, an Adjuvant System Containing α-Tocopherol and Squalene in an Oil-inWater Emulsion.” Expert Review of Vaccines 11 (3): 349–66. https://doi.org/10.1586/erv.11.192.
Glennie, Nelson D., Susan W. Volk, and Phillip Scott. 2017. “Skin-Resident CD4+ T Cells Protect
against Leishmania Major by Recruiting and Activating Inflammatory Monocytes.” PLOS
Pathogens 13 (4): e1006349. https://doi.org/10.1371/journal.ppat.1006349.
Glennie, Nelson D., Venkata A. Yeramilli, Daniel P. Beiting, Susan W. Volk, Casey T. Weaver,
and Phillip Scott. 2015. “Skin-Resident Memory CD4+ T Cells Enhance Protection against
Leishmania Major Infection.” The Journal of Experimental Medicine 212 (9): 1405.
https://doi.org/10.1084/jem.20142101.
González, Urbà, Mariona Pinart, Ludovic Reveiz, Monica Rengifo-Pardo, Jack Tweed, Antonio
Macaya, and Jorge Alvar. 2010. “Designing and Reporting Clinical Trials on Treatments for
Cutaneous Leishmaniasis.” Clinical Infectious Diseases 51 (4): 409–19.
https://doi.org/10.1086/655134.
Gray, Joshua I., Lotus M. Westerhof, and Megan K. L. MacLeod. 2018. “The Roles of Resident,
Central and Effector Memory CD4 T‐cells in Protective Immunity Following Infection or
Vaccination.” Immunology 154 (4): 574. https://doi.org/10.1111/imm.12929.

113

Gruber, R., and M. Schmuth. 2014. “Barrierefunktion der gesunden Haut.” Der Hautarzt 65 (3):
234–40. https://doi.org/10.1007/s00105-013-2691-1.
Grunwald, Thomas, and Sebastian Ulbert. 2015. “Improvement of DNA Vaccination by Adjuvants
and Sophisticated Delivery Devices: Vaccine-Platforms for the Battle against Infectious
Diseases.” Clinical and Experimental Vaccine Research 4 (1): 1–10.
https://doi.org/10.7774/cevr.2015.4.1.1.
Hagan, Thomas, Mario Cortese, Nadine Rouphael, Carolyn Boudreau, Caitlin Linde, Mohan S.
Maddur, Jishnu Das, et al. 2019. “Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity
to Vaccines in Humans.” Cell 178 (6): 1313-1328.e13. https://doi.org/10.1016/j.cell.2019.08.010.
Harris, Vanessa C., George Armah, Susana Fuentes, Katri E. Korpela, Umesh Parashar, John C.
Victor, Jacqueline Tate, et al. 2017. “Significant Correlation Between the Infant Gut Microbiome
and Rotavirus Vaccine Response in Rural Ghana.” The Journal of Infectious Diseases 215 (1):
34–41. https://doi.org/10.1093/infdis/jiw518.
Hartikka, J., M. Sawdey, F. Cornefert-Jensen, M. Margalith, K. Barnhart, M. Nolasco, H. L.
Vahlsing, et al. 1996. “An Improved Plasmid DNA Expression Vector for Direct Injection into
Skeletal Muscle.” Human Gene Therapy 7 (10): 1205–17. https://doi.org/10.1089/hum.1996.7.101205.
Henry, Conor M., Graeme P. Sullivan, Danielle M. Clancy, Inna S. Afonina, Dagmar Kulms, and
Seamus J. Martin. 2016. “Neutrophil-Derived Proteases Escalate Inflammation through Activation
of IL-36 Family Cytokines.” Cell Reports 14 (4): 708–22.
https://doi.org/10.1016/j.celrep.2015.12.072.

114

Hesse‐Macabata, J., B. Morgner, S. Morgenstern, M. O. Grimm, P. Elsner, U. C. Hipler, and C.
Wiegand. 2019. “Innate Immune Response of Human Epidermal Keratinocytes and Dermal
Fibroblasts to in Vitro Incubation of Trichophyton Benhamiae DSM 6916.” Journal of the
European Academy of Dermatology and Venereology 33 (6): 1177–88.
https://doi.org/10.1111/jdv.15472.
Hirao, Lauren A., David A. Hokey, Matthew P. Morrow, Maria N. Jure-Kunkel, and David B.
Weiner. 2011. “Immune Modulation through 4-1BB Enhances SIV Vaccine Protection in NonHuman Primates against SIVmac251 Challenge.” PLoS ONE 6 (9).
https://doi.org/10.1371/journal.pone.0024250.
Hokey, David A., Lauren A. Hirao, Sandra A. Calarota, Jian Yan, Jean D. Boyer, Anlan Dai,
Hanna Yoon, Maria N. Jure-Kunkel, Praveen Balimane, and David B. Weiner. 2007. “4-1BB
Antibody Significantly Enhances SIV-Specific CD8+ T-Cell Immunity and Proliferation Following
Naked DNA Vaccination in Cynomolgus Macaques (47.10).” The Journal of Immunology 178 (1
Supplement): S68–S68.
Iborra, Salvador, María Martínez-López, Sofía C. Khouili, Michel Enamorado, Francisco J. Cueto,
Ruth Conde-Garrosa, Carlos del Fresno, and David Sancho. 2016. “Optimal Generation of
Tissue-Resident but Not Circulating Memory T Cells during Viral Infection Requires Crosspriming
by DNGR-1 + Dendritic Cells.” Immunity 45 (4): 847–60.
https://doi.org/10.1016/j.immuni.2016.08.019.
Ichinohe, Takeshi, Iris K. Pang, Yosuke Kumamoto, David R. Peaper, John H. Ho, Thomas S.
Murray, and Akiko Iwasaki. 2011. “Microbiota Regulates Immune Defense against Respiratory
Tract Influenza A Virus Infection.” Proceedings of the National Academy of Sciences of the United
States of America 108 (13): 5354–59. https://doi.org/10.1073/pnas.1019378108.

115

Iho, Sumiko, Jun-ichi Maeyama, and Fumiko Suzuki. 2015. “CpG Oligodeoxynucleotides as
Mucosal Adjuvants.” Human Vaccines & Immunotherapeutics 11 (3): 755–60.
https://doi.org/10.1080/21645515.2014.1004033.
Jiang, Xiaodong, Rachael A. Clark, Luzheng Liu, Amy J. Wagers, Robert C. Fuhlbrigge, and
Thomas S. Kupper. 2012. “Skin Infection Generates Non-Migratory Memory CD8+ TRM Cells
Providing Global Skin Immunity.” Nature 483 (7388): 227–31.
https://doi.org/10.1038/nature10851.
Johnston, Andrew, Xianying Xing, Liza Wolterink, Drew H. Barnes, ZhiQiang Yin, Laura Reingold,
J. Michelle Kahlenberg, Paul W. Harms, and Johann E. Gudjonsson. 2017. “IL-1 and IL-36 Are
Dominant Cytokines in Generalized Pustular Psoriasis.” The Journal of Allergy and Clinical
Immunology 140 (1): 109–20. https://doi.org/10.1016/j.jaci.2016.08.056.
Kalams, Spyros A., Scott D. Parker, Marnie Elizaga, Barbara Metch, Srilatha Edupuganti, John
Hural, Stephen De Rosa, et al. 2013. “Safety and Comparative Immunogenicity of an HIV-1 DNA
Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation
for Delivery.” The Journal of Infectious Diseases 208 (5): 818–29.
https://doi.org/10.1093/infdis/jit236.
Kalams, Spyros A., Scott Parker, Xia Jin, Marnie Elizaga, Barbara Metch, Maggie Wang, John
Hural, et al. 2012. “Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults.” PLOS ONE 7
(1): e29231. https://doi.org/10.1371/journal.pone.0029231.
Kanazawa, Nobuo, Tomoyuki Nakamura, Naoya Mikita, and Fukumi Furukawa. 2013. “Novel
IL36RN Mutation in a Japanese Case of Early Onset Generalized Pustular Psoriasis.” The
Journal of Dermatology 40 (9): 749–51. https://doi.org/10.1111/1346-8138.12227.

116

Kardani, Kimia, Azam Bolhassani, and Sepideh Shahbazi. 2016. “Prime-Boost Vaccine Strategy
against Viral Infections: Mechanisms and Benefits.” Vaccine 34 (4): 413–23.
https://doi.org/10.1016/j.vaccine.2015.11.062.
Khalil, Eag, AMEl Hassan, Ee Zijlstra, Mm Mukhtar, Hw Ghalib, Breyma Musa, Me Ibrahim, et al.
2000. “Autoclaved Leishmania Major Vaccine for Prevention of Visceral Leishmaniasis: A
Randomised, Double-Blind, BCG-Controlled Trial in Sudan.” The Lancet 356 (9241): 1565–69.
https://doi.org/10.1016/S0140-6736(00)03128-7.
Khamesipour, A, Y Dowlati, A Asilian, R Hashemifesharki, A Javadi, S Noazin, and F Modabber.
2005. “Leishmanization: Use of an Old Method for Evaluation of Candidate Vaccines against
Leishmaniasis.” Vaccine 23 (28): 3642–48. https://doi.org/10.1016/j.vaccine.2005.02.015.
Khurana, Surender, Wanida Chearwae, Flora Castellino, Jody Manischewitz, Lisa R. King,
Agnieszka Honorkiewicz, Michael T. Rock, et al. 2010. “Vaccines with MF59 Adjuvant Expand the
Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus.” Science
Translational Medicine 2 (15): 15ra5-15ra5. https://doi.org/10.1126/scitranslmed.3000624.
Kovach, M A, B Singer, G Martinez-Colon, M W Newstead, X Zeng, P Mancuso, T A Moore, et al.
2017. “IL-36γ Is a Crucial Proximal Component of Protective Type-1-Mediated Lung Mucosal
Immunity in Gram-Positive and -Negative Bacterial Pneumonia.” Mucosal Immunology 10 (5):
1320–34. https://doi.org/10.1038/mi.2016.130.
Kutzler, Michele A., Tara M. Robinson, Michael A. Chattergoon, Daniel K. Choo, Andrew Y.
Choo, Philip Y. Choe, Mathura P. Ramanathan, et al. 2005. “Coimmunization with an Optimized
IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially
Independent of CD4 T Cell Help.” Journal of Immunology (Baltimore, Md.: 1950) 175 (1): 112–23.
https://doi.org/10.4049/jimmunol.175.1.112.

117

Kutzler, Michele A., and David B. Weiner. 2008. “DNA Vaccines: Ready for Prime Time?” Nature
Reviews. Genetics 9 (10): 776–88. https://doi.org/10.1038/nrg2432.
Lahiri, Amit, Priyanka Das, and Dipshikha Chakravortty. 2008. “Engagement of TLR Signaling as
Adjuvant: Towards Smarter Vaccine and Beyond.” Vaccine 26 (52): 6777–83.
https://doi.org/10.1016/j.vaccine.2008.09.045.
Lee, Sujin, and Minh Trang Nguyen. 2015. “Recent Advances of Vaccine Adjuvants for Infectious
Diseases.” Immune Network 15 (2): 51–57. https://doi.org/10.4110/in.2015.15.2.51.
Li, Ji-Kun, Jesse J. Balic, Liang Yu, and Brendan Jenkins. 2017. “TLR Agonists as Adjuvants for
Cancer Vaccines.” Advances in Experimental Medicine and Biology 1024: 195–212.
https://doi.org/10.1007/978-981-10-5987-2_9.
Li, Shuying S., Nidhi K. Kochar, Marnie Elizaga, Christine M. Hay, Gregory J. Wilson, Kristen W.
Cohen, Stephen C. De Rosa, et al. 2017. “DNA Priming Increases Frequency of T-Cell
Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ TCell Responses by Interleukin-12 Plasmid DNA.” Clinical and Vaccine Immunology: CVI 24 (11).
https://doi.org/10.1128/CVI.00263-17.
Liu, Luzheng, Qiong Zhong, Tian Tian, Krista Dubin, Shruti K. Athale, and Thomas S. Kupper.
2010. “Physical Disruption of Skin during Poxvirus Immunization Is Critical for the Generation of
Highly Protective T Cell-Mediated Immunity.” Nature Medicine 16 (2): 224–27.
https://doi.org/10.1038/nm.2078.
López‐Carvajal, Liliana, Iván Vélez, María Patricia Arbeláez, and Piero Olliaro. 2018. “Eligibility
Criteria and Outcome Measures Adopted in Clinical Trials of Treatments of Cutaneous
Leishmaniasis: Systematic Literature Review Covering the Period 1991–2015.” Tropical Medicine
& International Health 23 (5): 448–75. https://doi.org/10.1111/tmi.13048.
118

Losquadro, William D. 2017. “Anatomy of the Skin and the Pathogenesis of Nonmelanoma Skin
Cancer.” Facial Plastic Surgery Clinics of North America, Facial Reconstruction Post-Mohs
Surgery, 25 (3): 283–89. https://doi.org/10.1016/j.fsc.2017.03.001.
Mackay, Laura K., Angus T. Stock, Joel Z. Ma, Claerwen M. Jones, Stephen J. Kent, Scott N.
Mueller, William R. Heath, Francis R. Carbone, and Thomas Gebhardt. 2012. “Long-Lived
Epithelial Immunity by Tissue-Resident Memory T (TRM) Cells in the Absence of Persisting Local
Antigen Presentation.” Proceedings of the National Academy of Sciences 109 (18): 7037–42.
https://doi.org/10.1073/pnas.1202288109.
Maraghi, Sharif, Ata A. Ghadiri, Mehdi Tavalla, Saeedeh Shojaee, and Rahman Abdizadeh. 2019.
“Evaluation of Immunogenicity and Protective Effect of DNA Vaccine Encoding Surface Antigen1
(SAG1) of Toxoplasma Gondii and TLR-5 Ligand as a Genetic Adjuvant against Acute
Toxoplasmosis in BALB/c Mice.” Biologicals, October.
https://doi.org/10.1016/j.biologicals.2019.10.002.
McCormack, Sheena, Wolfgang Stöhr, Tristan Barber, Pierre-Alexandre Bart, Alexandre Harari,
Christiane Moog, Donatella Ciuffreda, et al. 2008. “EV02: A Phase I Trial to Compare the Safety
and Immunogenicity of HIV DNA-C Prime-NYVAC-C Boost to NYVAC-C Alone.” Vaccine 26 (25):
3162–74. https://doi.org/10.1016/j.vaccine.2008.02.072.
McKee, Amy S., Michael W. Munks, and Philippa Marrack. 2007. “How Do Adjuvants Work?
Important Considerations for New Generation Adjuvants.” Immunity 27 (5): 687–90.
https://doi.org/10.1016/j.immuni.2007.11.003.

119

Montgomery, D. L., J. W. Shiver, K. R. Leander, H. C. Perry, A. Friedman, D. Martinez, J. B.
Ulmer, J. J. Donnelly, and M. A. Liu. 1993. “Heterologous and Homologous Protection against
Influenza A by DNA Vaccination: Optimization of DNA Vectors.” DNA and Cell Biology 12 (9):
777–83. https://doi.org/10.1089/dna.1993.12.777.
Mosca, F., E. Tritto, A. Muzzi, E. Monaci, F. Bagnoli, C. Iavarone, D. O’Hagan, R. Rappuoli, and
E. De Gregorio. 2008. “Molecular and Cellular Signatures of Human Vaccine Adjuvants.”
Proceedings of the National Academy of Sciences of the United States of America 105 (30):
10501–6. https://doi.org/10.1073/pnas.0804699105.
Mou, Zhirong, Jintao Li, Thouraya Boussoffara, Hiroyuki Kishi, Hiroshi Hamana, Peyman Ezzati,
Chuanmin Hu, et al. 2015. “Identification of Broadly Conserved Cross-Species Protective
Leishmania Antigen and Its Responding CD4+ T Cells.” Science Translational Medicine 7
(October): 310ra167-310ra167. https://doi.org/10.1126/scitranslmed.aac5477.
Muthumani, Karuppiah, Bryan D. Griffin, Sangya Agarwal, Sagar B. Kudchodkar, Emma L.
Reuschel, Hyeree Choi, Kimberly A. Kraynyak, et al. 2016. “In Vivo Protection against ZIKV
Infection and Pathogenesis through Passive Antibody Transfer and Active Immunisation with a
PrMEnv DNA Vaccine.” Npj Vaccines 1 (1): 1–11. https://doi.org/10.1038/npjvaccines.2016.21.
Mutyambizi, K., C. L. Berger, and R. L. Edelson. 2009. “The Balance between Immunity and
Tolerance: The Role of Langerhans Cells.” Cellular and Molecular Life Sciences : CMLS 66 (5):
831–40. https://doi.org/10.1007/s00018-008-8470-y.
Nadim, A., E. Javadian, G. Tahvildar-Bidruni, and M. Ghorbani. 1983. “Effectiveness of
Leishmanization in the Control of Cutaneous Leishmaniasis.” Bulletin De La Societe De
Pathologie Exotique Et De Ses Filiales 76 (4): 377–83.

120

Nagy, István, and Lajos Kemény. 2009. “Skin Immune System.” In Life-Threatening Dermatoses
and Emergencies in Dermatology, edited by Jean Revuz, Jean-Claude Roujeau, Francisco A.
Kerdel, and Laurence Valeyrie-Allanore, 19–28. Berlin, Heidelberg: Springer.
https://doi.org/10.1007/978-3-540-79339-7_2.
Nemattalab, Mehran, Mohammad Shenagari, Mojtaba Taheri, Mohammad Mahjoob, Foroogh
Nazari Chamaki, Ali Mojtahedi, Elham Hasan-alizadeh, Babak Ashrafkhani, and Neda Mousavi
Niri. 2020. “Co-Expression of Interleukin-17A Molecular Adjuvant and Prophylactic Helicobacter
Pylori Genetic Vaccine Could Cause Sterile Immunity in Treg Suppressed Mice.” Cytokine 126
(February): 154866. https://doi.org/10.1016/j.cyto.2019.154866.
Nguyen-Hoai, T., M. Pham-Duc, M. Gries, B. Dörken, A. Pezzutto, and J. Westermann. 2016.
“CCL4 as an Adjuvant for DNA Vaccination in a Her2/Neu Mouse Tumor Model.” Cancer Gene
Therapy 23 (6): 162–67. https://doi.org/10.1038/cgt.2016.9.
Plotkin, Stanley. 2014. “History of Vaccination.” Proceedings of the National Academy of
Sciences of the United States of America 111 (34): 12283–87.
https://doi.org/10.1073/pnas.1400472111.
Podda, Audino. 2001. “The Adjuvanted Influenza Vaccines with Novel Adjuvants: Experience with
the MF59-Adjuvanted Vaccine.” Vaccine 19 (17): 2673–80. https://doi.org/10.1016/S0264410X(00)00499-0.
Ponte-Sucre, Alicia, Francisco Gamarro, Jean-Claude Dujardin, Michael P. Barrett, Rogelio
López-Vélez, Raquel García-Hernández, Andrew W. Pountain, Roy Mwenechanya, and Barbara
Papadopoulou. 2017. “Drug Resistance and Treatment Failure in Leishmaniasis: A 21st Century
Challenge.” PLoS Neglected Tropical Diseases 11 (12).
https://doi.org/10.1371/journal.pntd.0006052.

121

Ravi Vijaya Satya, Amar Mukherjee, and Udaykumar Ranga. 2003. “A Pattern Matching
Algorithm for Codon Optimization and CpG Motif-Engineering in DNA Expression Vectors.” In
Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE Bioinformatics
Conference. CSB2003, 294–305. Stanford, CA, USA: IEEE Comput. Soc.
https://doi.org/10.1109/CSB.2003.1227330.
Reed, Steven G., Mark T. Orr, and Christopher B. Fox. 2013. “Key Roles of Adjuvants in Modern
Vaccines.” Nature Medicine 19 (12): 1597–1608. https://doi.org/10.1038/nm.3409.
Resik, Sonia, Alina Tejeda, Pedro Mas Lago, Manuel Diaz, Ania Carmenates, Luis Sarmiento,
Nilda Alemañi, et al. 2010. “Randomized Controlled Clinical Trial of Fractional Doses of
Inactivated Poliovirus Vaccine Administered Intradermally by Needle-Free Device in Cuba.” The
Journal of Infectious Diseases 201 (9): 1344–52. https://doi.org/10.1086/651611.
Rogers, Kathleen A., Gregory K. DeKrey, M. Lamine Mbow, R. Dean Gillespie, Claudia I.
Brodskyn, and Richard G. Titus. 2002. “Type 1 and Type 2 Responses to Leishmania Major.”
FEMS Microbiology Letters 209 (1): 1–7. https://doi.org/10.1111/j.1574-6968.2002.tb11101.x.
Rogers, Matthew E., Thomas Ilg, Andrei V. Nikolaev, Michael A. J. Ferguson, and Paul A. Bates.
2004. “Transmission of Cutaneous Leishmaniasis by Sand Flies Is Enhanced by Regurgitation of
FPPG.” Nature 430 (6998): 463–67. https://doi.org/10.1038/nature02675.
Round, June L., and Sarkis K. Mazmanian. 2009. “The Gut Microbiota Shapes Intestinal Immune
Responses during Health and Disease.” Nature Reviews. Immunology 9 (5): 313–23.
https://doi.org/10.1038/nri2515.
Routy, Bertrand, Vancheswaran Gopalakrishnan, Romain Daillère, Laurence Zitvogel, Jennifer A.
Wargo, and Guido Kroemer. 2018. “The Gut Microbiota Influences Anticancer
Immunosurveillance and General Health.” Nature Reviews Clinical Oncology 15 (6): 382–96.
https://doi.org/10.1038/s41571-018-0006-2.
122

Saade, Fadi, and Nikolai Petrovsky. 2012. “Technologies for Enhanced Efficacy of DNA
Vaccines.” Expert Review of Vaccines 11 (2): 189–209. https://doi.org/10.1586/erv.11.188.
Sardesai, Niranjan Y., and David B. Weiner. 2011. “Electroporation Delivery of DNA Vaccines:
Prospects for Success.” Current Opinion in Immunology 23 (3): 421–29.
https://doi.org/10.1016/j.coi.2011.03.008.
Schadeck, Eva B., Maninder Sidhu, Michael A. Egan, Siew-Yen Chong, Priscilla Piacente, Amjed
Masood, Dorys Garcia-Hand, et al. 2006. “A Dose Sparing Effect by Plasmid Encoded IL-12
Adjuvant on a SIVgag-Plasmid DNA Vaccine in Rhesus Macaques.” Vaccine, DNA Vaccines, 24
(21): 4677–87. https://doi.org/10.1016/j.vaccine.2005.10.035.
Shah, Ruchi R., Kimberly J. Hassett, and Luis A. Brito. 2017. “Overview of Vaccine Adjuvants:
Introduction, History, and Current Status.” Vaccine Adjuvants, 1–13. https://doi.org/10.1007/9781-4939-6445-1_1.
Shahi, Maryam, Masoud Mohajery, Seyyed Ali Akbar Shamsian, Hossein Nahrevanian, and
Seyyed Mohammad Javad Yazdanpanah. 2013. “Comparison of Th1 and Th2 Responses in NonHealing and Healing Patients with Cutaneous Leishmaniasis.” Reports of Biochemistry &
Molecular Biology 1 (2): 43–48.
Shi, Na, Na Li, Xinwang Duan, and Haitao Niu. 2017. “Interaction between the Gut Microbiome
and Mucosal Immune System.” Military Medical Research 4: 14. https://doi.org/10.1186/s40779017-0122-9.
Shin, Haina, and Akiko Iwasaki. 2013. “Tissue-Resident Memory T Cells.” Immunological
Reviews 255 (1): 165–81. https://doi.org/10.1111/imr.12087.

123

Siddiqui, Imran, Karin Schaeuble, Vijaykumar Chennupati, Silvia A. Fuertes Marraco, Sandra
Calderon-Copete, Daniela Pais Ferreira, Santiago J. Carmona, et al. 2019. “Intratumoral
Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to
Vaccination and Checkpoint Blockade Immunotherapy.” Immunity 50 (1): 195-211.e10.
https://doi.org/10.1016/j.immuni.2018.12.021.
Sin, Jeong-Im, Jong J. Kim, Renee L. Arnold, Khushroo E. Shroff, Don McCallus, Cathy Pachuk,
Sue P. McElhiney, et al. 1999. “IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse
Model: IL-12 Enhances Th1-Type CD4+ T Cell-Mediated Protective Immunity Against Herpes
Simplex Virus-2 Challenge.” The Journal of Immunology 162 (5): 2912–21.
Sundar, Shyam, and Bhawana Singh. 2014. “Identifying Vaccine Targets for Anti-Leishmanial
Vaccine Development.” Expert Review of Vaccines 13 (4): 489.
https://doi.org/10.1586/14760584.2014.894467.
Sunyoto, Temmy, Julien Potet, and Marleen Boelaert. 2018. “Why Miltefosine—a Life-Saving
Drug for Leishmaniasis—Is Unavailable to People Who Need It the Most.” BMJ Global Health 3
(3). https://doi.org/10.1136/bmjgh-2018-000709.
Suschak, John J., James A. Williams, and Connie S. Schmaljohn. 2017. “Advancements in DNA
Vaccine Vectors, Non-Mechanical Delivery Methods, and Molecular Adjuvants to Increase
Immunogenicity.” Human Vaccines & Immunotherapeutics 13 (12): 2837–48.
https://doi.org/10.1080/21645515.2017.1330236.
Takamura, Shiki. 2018. “Niches for the Long-Term Maintenance of Tissue-Resident Memory T
Cells.” Frontiers in Immunology 9. https://doi.org/10.3389/fimmu.2018.01214.

124

Tang, De-chu, Michael DeVit, and Stephen A. Johnston. 1992. “Genetic Immunization Is a Simple
Method for Eliciting an Immune Response.” Nature 356 (6365): 152–54.
https://doi.org/10.1038/356152a0.
Taylor, C. E. 1995. “Cytokines as Adjuvants for Vaccines: Antigen-Specific Responses Differ from
Polyclonal Responses.” Infection and Immunity 63 (9): 3241–44.
Tebas, Pablo, Christine C. Roberts, Kar Muthumani, Emma L. Reuschel, Sagar B. Kudchodkar,
Faraz I. Zaidi, Scott White, et al. 2017. “Safety and Immunogenicity of an Anti-Zika Virus DNA
Vaccine - Preliminary Report.” The New England Journal of Medicine, October.
https://doi.org/10.1056/NEJMoa1708120.
Temizoz, Burcu, Etsushi Kuroda, and Ken J. Ishii. 2016. “Vaccine Adjuvants as Potential Cancer
Immunotherapeutics.” International Immunology 28 (7): 329–38.
https://doi.org/10.1093/intimm/dxw015.
Tomai, Mark A., and John P. Vasilakos. 2012. “TLR Agonists as Vaccine Adjuvants.” In
Innovation in Vaccinology: From Design, through to Delivery and Testing, edited by Selene
Baschieri, 205–28. Dordrecht: Springer Netherlands. https://doi.org/10.1007/978-94-007-45438_9.
Tovey, Michael G., and Christophe Lallemand. 2010. “Adjuvant Activity of Cytokines.” Methods in
Molecular Biology (Clifton, N.J.) 626: 287–309. https://doi.org/10.1007/978-1-60761-585-9_19.
Towne, Jennifer E., Blair R. Renshaw, Jason Douangpanya, Brian P. Lipsky, Min Shen,
Christopher A. Gabel, and John E. Sims. 2011. “Interleukin-36 (IL-36) Ligands Require
Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) Activity.” The
Journal of Biological Chemistry 286 (49): 42594–602. https://doi.org/10.1074/jbc.M111.267922.

125

Trimble, Cornelia L., Matthew P. Morrow, Kimberly A. Kraynyak, Xuefei Shen, Michael Dallas,
Jian Yan, Lance Edwards, et al. 2015. “Safety, Efficacy, and Immunogenicity of VGX-3100, a
Therapeutic Synthetic DNA Vaccine Targeting Human Papillomavirus 16 and 18 E6 and E7
Proteins for Cervical Intraepithelial Neoplasia 2/3: A Randomised, Double-Blind, PlaceboControlled Phase 2b Trial.” Lancet (London, England) 386 (10008): 2078–88.
https://doi.org/10.1016/S0140-6736(15)00239-1.
Tugues, S., S. H. Burkhard, I. Ohs, M. Vrohlings, K. Nussbaum, J. Vom Berg, P. Kulig, and B.
Becher. 2015. “New Insights into IL-12-Mediated Tumor Suppression.” Cell Death and
Differentiation 22 (2): 237–46. https://doi.org/10.1038/cdd.2014.134.
Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H.
Gromkowski, et al. 1993. “Heterologous Protection against Influenza by Injection of DNA
Encoding a Viral Protein.” Science 259 (5102): 1745–49.
https://doi.org/10.1126/science.8456302.
Vélez, Iván D., Katherine Gilchrist, María P. Arbelaez, Carlos A. Rojas, Juan A. Puerta, Carlos
M.F. Antunes, Fabio Zicker, and Farrokh Modabber. 2005. “Failure of a Killed Leishmania
Amazonensis Vaccine against American Cutaneous Leishmaniasis in Colombia.” Transactions of
the Royal Society of Tropical Medicine and Hygiene 99 (8): 593–98.
https://doi.org/10.1016/j.trstmh.2005.04.002.
Verma, Akash H., Hanna Zafar, Nicole O. Ponde, Olivia W. Hepworth, Diksha Sihra, Felix E. Y.
Aggor, Joseph S. Ainscough, et al. 2018. “IL-36 and IL-1/IL-17 Drive Immunity to Oral Candidiasis
via Parallel Mechanisms.” The Journal of Immunology 201 (2): 627–34.
https://doi.org/10.4049/jimmunol.1800515.

126

Vigne, Solenne, Gaby Palmer, Céline Lamacchia, Praxedis Martin, Dominique Talabot-Ayer,
Emiliana Rodriguez, Francesca Ronchi, et al. 2011. “IL-36R Ligands Are Potent Regulators of
Dendritic and T Cells.” Blood 118 (22): 5813–23. https://doi.org/10.1182/blood-2011-05-356873.
Vigne, Solenne, Gaby Palmer, Praxedis Martin, Céline Lamacchia, Deborah Strebel, Emiliana
Rodriguez, Maria L. Olleros, et al. 2012. “IL-36 Signaling Amplifies Th1 Responses by Enhancing
Proliferation and Th1 Polarization of Naive CD4+ T Cells.” Blood 120 (17): 3478–87.
https://doi.org/10.1182/blood-2012-06-439026.
Villarreal, Daniel O., Rebekah J. Siefert, and David B. Weiner. 2015. “Alarmin IL-33 Elicits Potent
TB-Specific Cell-Mediated Responses.” Human Vaccines & Immunotherapeutics 11 (8): 1954–60.
https://doi.org/10.1080/21645515.2015.1026499.
Villarreal, Daniel O., and David B. Weiner. 2014. “Interleukin 33: A Switch-Hitting Cytokine.”
Current Opinion in Immunology 28 (June): 102–6. https://doi.org/10.1016/j.coi.2014.03.004.
Villarreal, Daniel O., Megan C. Wise, Jewell N. Walters, Emma L. Reuschel, Min Joung Choi,
Nyamekye Obeng-Adjei, Jian Yan, Matthew P. Morrow, and David B. Weiner. 2014. “Alarmin IL33 Acts as an Immunoadjuvant to Enhance Antigen-Specific Tumor Immunity.” Cancer Research
74 (6): 1789–1800. https://doi.org/10.1158/0008-5472.CAN-13-2729.
Wang, B., K. E. Ugen, V. Srikantan, M. G. Agadjanyan, K. Dang, Y. Refaeli, A. I. Sato, J. Boyer,
W. V. Williams, and D. B. Weiner. 1993. “Gene Inoculation Generates Immune Responses
against Human Immunodeficiency Virus Type 1.” Proceedings of the National Academy of
Sciences 90 (9): 4156–60. https://doi.org/10.1073/pnas.90.9.4156.

127

Wang, Peng, Ana M. Gamero, and Liselotte E. Jensen. 2019. “IL-36 Promotes Anti-Viral
Immunity by Boosting Sensitivity to IFN-α/β in IRF1 Dependent and Independent Manners.”
Nature Communications 10 (October). https://doi.org/10.1038/s41467-019-12318-y.
Wang, Shixia, Diego J. Farfan-Arribas, Siyuan Shen, Te-Hui W. Chou, Allison Hirsch, Feng He,
and Shan Lu. 2006. “Relative Contributions of Codon Usage, Promoter Efficiency and Leader
Sequence to the Antigen Expression and Immunogenicity of HIV-1 Env DNA Vaccine.” Vaccine
24 (21): 4531–40. https://doi.org/10.1016/j.vaccine.2005.08.023.
Wang, Xuefeng, Xin Zhao, Chao Feng, Aliyah Weinstein, Rui Xia, Wen Wen, Quansheng Lv, et
al. 2015a. “IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 LymphocyteMediated Antitumor Immune Responses.” Cancer Cell 28 (3): 296.
https://doi.org/10.1016/j.ccell.2015.07.014.
———. 2015b. “IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1
Lymphocyte-Mediated Antitumor Immune Responses.” Cancer Cell 28 (3): 296–306.
https://doi.org/10.1016/j.ccell.2015.07.014.
Wen, Yumei, and Yan Shi. 2016. “Alum: An Old Dog with New Tricks.” Emerging Microbes &
Infections 5 (3): e25–e25. https://doi.org/10.1038/emi.2016.40.
Wilkins, Amanda L., Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran,
Claire-Anne Siegrist, and Andrew J. Pollard. 2017. “AS03- and MF59-Adjuvanted Influenza
Vaccines in Children.” Frontiers in Immunology 8. https://doi.org/10.3389/fimmu.2017.01760.
Winkle, Sean M., Andrea L. Throop, and Melissa M. Herbst-Kralovetz. 2016. “IL-36γ Augments
Host Defense and Immune Responses in Human Female Reproductive Tract Epithelial Cells.”
Frontiers in Microbiology 7 (June). https://doi.org/10.3389/fmicb.2016.00955.

128

Woodland, David L. 2004. “Jump-Starting the Immune System: Prime-Boosting Comes of Age.”
Trends in Immunology 25 (2): 98–104. https://doi.org/10.1016/j.it.2003.11.009.
Zhou, Ming, Guoqing Zhang, Guiping Ren, Clement W. Gnanadurai, Zhenguang Li, Qingqing
Chai, Yang Yang, et al. 2013. “Recombinant Rabies Viruses Expressing GM-CSF or Flagellin Are
Effective Vaccines for Both Intramuscular and Oral Immunizations.” PLOS ONE 8 (5): e63384.
https://doi.org/10.1371/journal.pone.0063384.

129

